Systems and methods for generating hyperpolarized compounds using secondary hydrogen.

By introducing unsaturated chemical bonds and secondary hydrogenation reactions into the precursor molecules, combined with magnetic resonance pulse sequences, the problems of insufficient sample volume, purity, and concentration in existing hyperpolarization MRI methods have been solved, enabling the production of high-purity and high-concentration hyperpolarization bio-related imaging agents, supporting clinical applications.

CN117242361BActive Publication Date: 2026-11-17NVISION QUANTUM TECHNOLOGIES GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180093080.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-07-23
Filing Date
2021-12-07
Publication Date
2026-11-17
Estimated Expiration
2041-12-07

AI Technical Summary

Technical Problem

Existing hyperpolarization MRI methods cannot produce sufficient sample volume, purity, and concentration of biorelevant imaging agents, limiting their application in preclinical or clinical settings.

Method used

Using PHIP-SAH technology, unsaturated chemical bonds are introduced into the precursor molecule, and the spin level is transferred to the target nucleus by secondary hydrogenation reaction and magnetic resonance pulse sequence under a magnetic field of 0 mT to 500 mT to generate hyperpolarized target compounds. High-concentration solutions are then formed through purification and redissolution of the precipitate.

Benefits of technology

This technology enables the production of high-purity and high-concentration hyperpolarized biorelevant imaging agents within clinically relevant volumes, solving the problems of insufficient sample volume, purity, and concentration in existing technologies and supporting clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117242361B_ABST
    Figure CN117242361B_ABST
Patent Text Reader

Abstract

Systems and methods for increasing nuclear spin polarization in a target compound are disclosed. Nuclear spin polarization can be increased by obtaining the target compound or a precursor thereof. The target compound or the precursor may contain a first proton and a second proton sharing a singlet spin level, and a third proton coupled to at least one of the first proton or the second proton. The target atom may be coupled to at least the third proton. The precursor may be placed within an average magnetic field strength of less than 500 mT. A magnetic resonance (MR) pulse sequence may be applied to the precursor, the MR pulse sequence being configured to transfer the population from the first proton and the second proton to the target atom, thereby imparting at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-referencing related applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 201,151, filed April 15, 2021. This application claims the benefit of U.S. Provisional Patent Application No. 63 / 122,006, filed December 7, 2020. This application claims the benefit of International Application No. PCT / IB2021 / 000493, filed July 23, 2021, which in turn claims the benefit of U.S. Provisional Application No. 63 / 055,367, filed July 23, 2020. International Application No. PCT / IB2021 / 000493 also claims the benefit of U.S. Provisional Application No. 63 / 076,411, filed September 10, 2020. Each of the above applications is incorporated herein by reference in its entirety. Technical Field

[0003] The disclosed embodiments typically relate to the generation of hyperpolarized materials for nuclear magnetic resonance, magnetic resonance imaging, or similar applications. Background Technology

[0004] Secondary hydrogen-induced polarization (PHIP) is a low-cost, high-throughput method for polarization metabolites in hyperpolarization (HP) magnetic resonance imaging (MRI). PHIP, PHIP-SAH with lateral arm hydrogenation, and signal amplification via reversible exchange (SABRE) can be used for polarization metabolites such as fumarates or pyruvate. However, existing polarization methods may not be suitable for preclinical or clinical hyperpolarization MRI applications because they may not achieve sufficient sample volume, purity, polarization, or concentration. Summary of the Invention

[0005] The disclosed systems and methods relate to the generation of hyperpolarized target compounds using at least one of PHIP, PHIP-SAH, or SABRE. The generation of hyperpolarized materials may involve the application of a sequence of microwave pulses or modulation of a magnetic field. In some embodiments, the target compound may be hyperpolarized in solution and then induced to precipitate from that solution. The precipitate may be redissolved in a specified volume of solvent to form a solution of the hyperpolarized target compound with a desired concentration. Polarization may be achieved using a mediator atom that transfers from the spin states of two hydrogen atoms to the spin state of the target atom, the mediator atom forming a quantum three-body system with the target atom.

[0006] The disclosed embodiments include a system for generating hyperpolarized molecules. The system may include a hydrogenation device, a polarization device, an RF waveform generator, and a purification system. The hydrogenation device may be configured to generate a secondary hydrogenated solution by mixing a solvent, secondary hydrogen gas, and a precursor of the hyperpolarized molecules, said precursor comprising unsaturated chemical bonds. The polarization device may be configured to use the secondary hydrogenated solution to generate a polarized solution containing the hyperpolarized molecules. The polarization device may include a polarization chamber, one or more radio frequency (RF) coils, and a magnetic field source. The polarization chamber may be configured to receive the secondary hydrogenated solution. The polarization chamber may contain a polarization region with a volume of at least 10 milliliters (mL). One or more RF coils may be disposed around the polarization region of the polarization chamber. The magnetic field source may be disposed around the polarization region of the polarization chamber and configured to provide an average magnetic field strength of up to 200 millitalas (mT). The RF waveform generator may be coupled to one or more RF coils of the polarization device. The RF waveform generator may be configured to apply an RF waveform to said one or more RF coils. The purification system can be configured to separate purified fractions from the polarized solution.

[0007] The disclosed embodiments include a method for increasing nuclear spin polarization in a target compound. The method may include: obtaining a target compound or a secondary hydrogenated precursor of a target compound; placing the target compound or secondary hydrogenated precursor within an average magnetic field strength below 500 mT; and applying a magnetic resonance (MR) pulse sequence to the target compound or secondary hydrogenated precursor. The obtained target compound or secondary hydrogenated precursor may comprise (i) a first proton, (ii) a second proton coupled to at least the first proton via a first J coupling constant, the first and second protons having a singlet spin order, (iii) a third proton coupled to at least one of the first or second proton via a second J coupling constant, and (iv) a target atom coupled to at least the third proton via a third J coupling constant. The first and second protons may be separated from the target atom by at least four chemical bonds. The MR pulse sequence may be configured to transfer the population from the first and second protons to the target atom, thereby imparting at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom.

[0008] The disclosed embodiments further include a method for generating a hyperpolarized molecule. The method may include the following operations: obtaining a precursor of the molecule; performing a secondary hydrogen-induced polarization (PHIP) reaction between a secondary hydrogen and the precursor; placing the molecule within an average magnetic field strength between 0 mT and 500 mT; applying a magnetic resonance (MR) pulse sequence to the molecule; cleaving the side arm from the precursor, thereby generating a hyperpolarized molecule and the cleaved side arm; purifying the hyperpolarized molecule from the cleaved side arm; administering the hyperpolarized molecule to a subject; and performing a hyperpolarized magnetic resonance imaging (MRI) procedure on the subject. The precursor may comprise the molecule and a side arm coupled to the molecule, the molecule including a target atom, and the side arm including at least one unsaturated chemical bond separated from the target atom by at least three intermediate chemical bonds. Performing the secondary hydrogen-induced polarization (PHIP) reaction may add a first proton and a second proton across the at least one unsaturated bond and form the molecule. The MR pulse sequence may be configured to transfer a population from the first and second protons to the target atom. The MR pulse sequence can thus impart at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom.

[0009] It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only, and are not intended to limit the disclosed embodiments as claimed. Attached Figure Description

[0010] The accompanying drawings, which form part of this specification, illustrate several embodiments and, together with the description, serve to explain the principles and features of the disclosed embodiments. In the drawings:

[0011] Figure 1 An exemplary process for PHIP or PHIP-SAH polarization, consistent with the disclosed embodiments, is shown.

[0012] Figure 2A A quantum mechanical four-body system suitable for using proton transfer polarization, consistent with the disclosed embodiments, is described.

[0013] Figure 2B The disclosed embodiments are consistent with those disclosed. Figure 2A The approximate energy structure of the quantum mechanical three-body system of protons described in the book.

[0014] Figure 3 The embodiments consistent with those disclosed are depicted. Figure 2A Simulation and calculation of the PulsePol transfer efficiency of spin systems in [the text].

[0015] Figure 4 An exemplary schematic diagram of a polarizer for obtaining a high-concentration biocompatible solution containing a hyperpolarized target compound is depicted.

[0016] Figure 5A , 5B Each of the two diagrams depicts an exemplary schematic of a system comprising a polarizer and a separation system, wherein the polarizer is used to obtain a high-concentration biocompatible solution containing a hyperpolarized target compound.

[0017] Figure 6A An exemplary schematic diagram of a system for generating hyperpolarized target compounds, consistent with the disclosed embodiments, is depicted.

[0018] Figures 6B to 6D Frequency and amplitude characteristics suitable for using radio frequency sweeps mediated by proton transfer polarization, consistent with the disclosed embodiments, are described.

[0019] Figure 6E The description is consistent with the disclosed embodiments, and is based on... Figures 6B to 6D During the application of radio frequency sweeping, in planes transverse and parallel to the static magnetic field 13 C polarization.

[0020] Figure 7A and 7B Simulation and experimental results depicting the polarization transfer of protonated and deuterated cinnamic acid molecules according to the disclosed embodiments are presented.

[0021] Figure 7C Polarizations implemented according to the disclosed embodiments of DAMD-d6, DMAD, fumarate, CP 1-13C d1, and CP are shown.

[0022] Figure 8 The polarized 25ml 1- is described according to the disclosed embodiments. 13 C-C cinnamon ester sample.

[0023] Figure 9 The measurements taken in a 60 MHz SpinSolve spectrometer are depicted. Figure 8 The polarization depicted in the text is rich in 13 Cinnamyl pyruvate 13 C NMR spectrum. Detailed Implementation

[0024] Exemplary embodiments discussed with reference to the accompanying drawings will now be described in detail. In some cases, the same reference numerals will be used throughout the drawings and in the following description to refer to the same or similar parts. Unless otherwise defined, technical or scientific terms have the meanings commonly understood by one of ordinary skill in the art. The disclosed embodiments have been described in sufficient detail to enable those skilled in the art to practice the disclosed embodiments. It should be understood that other embodiments may be utilized and changes may be made without departing from the scope of the disclosed embodiments. Therefore, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0025] Recent work in the fields of nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI) has demonstrated that, using various so-called hyperpolarization techniques, NMR and MRI signals associated with a wide range of biorelevant imaging agents can be enhanced by orders of magnitude. This dramatic signal enhancement allows for the spectral analysis of these biorelevant imaging agents, as they are metabolized by various tissues at different locations within the body. Analysis of the metabolic information determined through such spectral imaging allows for the non-invasive determination of the health status of tissues within the body. For example, abnormal metabolism of biorelevant imaging agents may predict diseases such as cancer in certain locations of the body.

[0026] Existing techniques for hyperpolarized biorelevant imaging agents include dissolution dynamic nuclear polarization (DNP), secondary hydrogen-induced polarization (PHIP), PHIP side-arm hydrogenation (PHIP-SAH), and signal amplification via reversible exchange (SABRE). However, apart from DNP, existing techniques cannot produce clinically relevant volumes and concentrations of biorelevant imaging agents with sufficient polarization and purity. DNP has several drawbacks, including expensive instrumentation and the long time required for polarization establishment.

[0027] PHIP-SAH technology expands the application of PHIP-based polarization methods in the preparation of biorelevant imaging agents. In PHIP-SAH, a precursor molecule is hydrogenated and then cleaved. The precursor molecule typically includes a side arm containing unsaturated chemical bonds (such as carbon-carbon double or triple bonds), which is chemically linked to the biorelevant imaging agent. For example, the side arm can be positioned on the side of a carboxyl group, allowing the side arm and the biorelevant imaging agent to combine to form an ester precursor. The side arm then reacts with secondary hydrogen, allowing a proton with a high level of spin to pass through the unsaturated bond. This spin level is then transferred to a target nucleus (such as the nucleus of a 13C target atom) located in the biorelevant imaging agent. The side arm is then cleaved and removed, resulting in a solution containing the biorelevant imaging agent with a hyperpolarized target nucleus.

[0028] Unfortunately, previous PHIP-SAH techniques typically required unsaturated bonds to be located no more than two bonds away from the target atom, so that at least one secondary hydrogen proton would end up within three bonds of the target atom to achieve sufficiently strong coupling. This restriction imposed a major constraint on the precursor, reducing the practicality of the PHIP-SAH method. Such existing methods generally require a trade-off between the chemical stability of the precursor and the ease of adding secondary hydrogens to the unsaturated bonds.

[0029] Therefore, there is a need for hyperpolarized methods and systems that utilize PHIP-SAH precursor molecules, wherein unsaturated bonds are located at least three chemical bonds away from the target atom, such that each secondary hydrogen proton is ultimately at least four chemical bonds away from the target atom, thereby allowing the production of clinically relevant volumes of hyperpolarized biorelevant imaging agents.

[0030] The disclosed embodiments include systems and methods for generating target compounds (also known as target molecules), such as biorelevant imaging agents, with clinically relevant polarization, concentration, volume, and purity. The disclosed embodiments provide technical improvements for polarizing target compounds in solution. These technical improvements support increases in target compound concentration, the degree of target compound polarization, and solution volume.

[0031] The systems and methods described herein utilize PHIP-SAH precursor molecules containing targets located at a distance from the target atom or nucleus (e.g., on biorelevant imaging molecules). 13 The target nucleus (C) consists of at least three unsaturated chemical bonds. Secondary hydrogens are added to these unsaturated bonds, such that each of the two secondary hydrogen protons is located at least four chemical bonds away from the target atom or nucleus. Mediating protons located between the secondary hydrogen protons and the target nucleus form a quantum mechanical spin network, which is manipulated to transfer the spin order from the secondary hydrogen protons to the target nucleus, resulting in hyperpolarization of the target nucleus. Radio frequency (RF) excitation is used to drive the conversion of the secondary hydrogen spin order to target nucleus polarization under a magnetic field readily generated between 0 mT and 500 mT. Operating in this state allows for the expansion of polarization transfer to clinically relevant volumes. Because the unsaturated chemical bonds are located further away from the target nucleus, the precursor molecule is less susceptible to trade-offs between different optimization parameters, such as chemical stability and the ease of adding secondary hydrogens to the unsaturated chemical bonds. Therefore, precursor molecules can be better optimized to allow for the production of clinically relevant volumes of hyperpolarized biorelevant imaging agents, such as pyruvate, acetate, other carboxylic acid esters, and other clinically relevant target compounds that utilize unsaturated side arms for secondary hydrogen-based polarization.

[0032] Electromagnets, with or without ferromagnetic cores, can be used to generate such low magnetic fields in large volumes (e.g., clinically relevant volumes). Magnetic shielding can be added to increase uniformity throughout the large volume. Therefore, larger quantities (e.g., clinically relevant volumes) of more highly polarized target compounds can be produced.

[0033] The disclosed embodiments can be used together or alone. For example, the disclosed improvements to the polarization of the target compound can be used in conjunction with the disclosed improved separation method or other separation methods. Similarly, the disclosed improvements to the separation of the target compound can be used in conjunction with the disclosed improved polarization method or other polarization methods.

[0034] Consistent with the disclosed embodiments, secondary hydrogen can be used as a polarization source. As described herein, secondary hydrogen is a form of molecular hydrogen in which both proton spins are in a singlet state. The disclosed embodiments are not limited to specific methods for producing secondary hydrogen. Secondary hydrogen can be formed in gaseous or liquid form. Secondary hydrogen can be produced in gaseous form by passing hydrogen gas through a chamber containing a catalyst (e.g., iron oxide or another suitable catalyst) at a low temperature (e.g., extremely cold temperatures, such as temperatures between the boiling points of liquid helium and liquid nitrogen). The hydrogen gas may contain both secondary and normal hydrogen. The low temperature allows the hydrogen gas to reach thermodynamic equilibrium within the chamber, increasing the population of secondary hydrogen. The disclosed embodiments are not limited to specific locations for secondary hydrogen production. Secondary hydrogen can be produced at a first location and subsequently transported to a second location for use. In some embodiments, the first location can be a chamber, which may be part of a container, bottle, shelf, or other area capable of containing a gas or liquid. Such a chamber can be maintained at a suitable pressure or temperature. In some embodiments, the first location may refer to a physical location, such as a room, laboratory, specific warehouse, hospital, or other location where secondary hydrogen can be produced. The disclosed embodiments are not limited to specific methods for transporting secondary hydrogen. The generated secondary hydrogen can be transported in a chamber, which may be different from the chamber that generated the secondary hydrogen. The chamber for transporting the secondary hydrogen can be maintained at a suitable pressure or temperature, and it can be transported by vehicle or personnel. Transporting secondary hydrogen can involve moving the secondary hydrogen from one container to a different container. Transporting secondary hydrogen can involve moving the secondary hydrogen within the same location, such as from one part of a room to another part of the room. Transporting secondary hydrogen can involve moving the secondary hydrogen from one room in a building to a different room in the same building or a nearby building. Transporting secondary hydrogen can involve moving the secondary hydrogen to a different location in another part of the same city or to a different city. Transporting secondary hydrogen can involve bringing the secondary hydrogen near a polarizer or NMR / MRI device. Transporting secondary hydrogen can involve packaging or transporting the secondary hydrogen in a suitable container.

[0035] The population between spin states can be the difference between the populations of two spin states divided by the total population of those two spin states. The population can be expressed as a fractional population or a percentage population. In some embodiments, the fractional population is at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or greater. In some embodiments, the fractional population is at most about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, or less. In some embodiments, the fractional population falls within a range defined by any two of the foregoing values.

[0036] Hydrogen can exhibit a population difference between proton spin states that is significantly greater than that at thermal equilibrium. Secondary hydrogen can have a large population difference between singlet and any triplet spin state. In I... z1 I z2 In the case of the high-level, such as those achieved by hydrogenation under a high magnetic field, there is a large population difference between, for example, the spin states |↑>|↓> and |↑>|↑>. The population difference of proton spin states can be greater than about 0.1 (e.g., a 10% difference in spin states—55% of the secondary hydrogen molecules in the sample are in singlet state and 45% are in triplet state), 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or greater; or it can be less than about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or smaller.

[0037] The target compound may contain materials suitable for NMR or MRI manipulation (e.g., "NMR material"). In some embodiments, such NMR materials may enhance NMR / MRI signal and signal-to-noise ratio (SNR). In some embodiments, the NMR material may be suitable for solution NMR spectroscopy. In some embodiments, the NMR material may be a metabolite (e.g., a biologically relevant molecule such as an amino acid, sugar, its derivatives, etc.), such as a metabolite suitable for use in NMR metabolomics applications. In some embodiments, the NMR material may be suitable for in vitro detection of metabolism in cell cultures or other biological tissues. In some embodiments, the NMR material may be used in NMR probes to study transient effects where high signal enhancement is required due to hyperpolarization, such as proton exchange between water and biomolecules. In some embodiments, the NMR material may be a small molecule or metabolite suitable for injection into cells, tissues, or organisms for detection in MRI scans. In some embodiments, the NMR material may be introduced into a chamber for further analysis by NMR or MRI manipulation. In some embodiments, the NMR material may be enriched with 13C atoms. In some embodiments, the NMR material may be a biocompatible material that does not necessarily have metabolic functions.

[0038] Consistent with the disclosed embodiments, the target compound may be pyruvate, lactate, bicarbonate, fumarate, urea, α-ketoglutarate, dehydroascorbate, glutamate, glutamine, acetate, dihydroxyacetone, acetoacetate, glucose, ascorbate, fermentation ester, imidazole, nicotinamide, nitroimidazole, pyrazinamide, isoniazid, the conjugate acid of any of the foregoing, natural and non-natural amino acids, their esters, or esters rich in any of the foregoing. 13 C or 15 The form of N.

[0039] Consistent with the disclosed embodiments, the target compound can be generated from a “precursor” of the target compound. Such generation can involve one or more chemical reactions. In some embodiments, the target compound can be generated from a precursor by hydrogenation of one or more unsaturated bonds (e.g., unsaturated carbon-carbon bonds) of the precursor. For example, when the target compound is a fumarate, one or more unsaturated bonds of acetylenic acid dicarboxylic acid can be hydrogenated to produce fumaric acid. In some embodiments, the target compound can be generated from a precursor by cleaving a side arm from the precursor to generate the target compound. In some embodiments, the precursor can be an ester having the general formula -COOR. Thus, in such embodiments, the term “side arm” can refer to the R portion of the ester. In some embodiments, the side arm can contain substituents and functional groups directly bonded to the ester oxygen bound through the carbons on both sides. For example, the precursor can be an enol or alkynol ester of the target compound, wherein a particular enol or alkynol can be referred to as a side arm. As another example, the target compound can be a pyruvate. When the precursor is vinyl pyruvate and the side arm is a vinyl functional group. When the precursor is cinnamic acid ester, the side arm is a phenylallyl functional group. When the precursor is allyl pyruvate, the side arm is an allyl functional group. When the precursor is propargyl pyruvate, the side arm is a propargyl functional group. In some embodiments, the target compound can be generated from the precursor by hydrogenation and cleavage of the side arm. For example, the precursor can be hydrogenated, and the side arm can then be cleaved to generate the target compound. Hydrogenation can occur at a location on the side arm or on the target compound.

[0040] Consistent with the disclosed embodiments, hydrogenation can be performed using secondary hydrogenation (e.g., secondary hydrogenation). Such secondary hydrogenation can generate a proton spin population in the secondary hydrogenation precursor. Consistent with the disclosed embodiments, the proton spin population can be transferred to polarization on the target nucleus spin of the secondary hydrogenation precursor, thereby producing a hyperpolarized secondary hydrogenation precursor. When the target compound is generated from the precursor by hydrogenation, the hyperpolarized secondary hydrogenation precursor can be a hyperpolarized target compound. When the target compound is generated from the precursor by hydrogenation and cleaving of side arms, the hyperpolarized secondary hydrogenation precursor can be cleaved to produce a hyperpolarized target compound.

[0041] Various embodiments of this disclosure disclose methods for preparing hyperpolarized target compounds. In some embodiments, the target compound can be generated from a precursor by secondary hydrogenation and polarization using PHIP or SABRE, while in other embodiments, the target compound can be generated from a precursor using PHIP-SAH followed by cleaving of the side arms via secondary hydrogenation and polarization.

[0042] Figure 1 An exemplary process 100 for PHIP or PHIP-SAH polarization, consistent with the disclosed embodiments, is shown. Process 100 can be used for large-scale PHIP polarization to produce target compounds for in vitro or in vivo MRI. A similar process can be used for SABRE polarization, wherein the hydrogenation in step 105 is replaced by the exchangeable binding of the target compound and secondary hydrogen with the polarization catalyst. This description of process 100 is not intended to be limiting. Contemplated embodiments may include additional or fewer steps; or the steps may be combined or separated. For example, process 100 may begin at step 105 using previously generated or obtained secondary hydrogen. As another example, method 100 may terminate in step 109 by purifying or isolating the target compound. Similarly, the transport in steps 103 and 111 may be optional. Furthermore, although described for use in MRI, the target compound is not necessarily limited to such uses.

[0043] Consistent with the disclosed embodiments, optional step 101 of process 100 describes the generation of secondary hydrogen. Secondary hydrogen can be generated by passing a cold hydrogen stream through a chamber containing a catalyst such as iron oxide, allowing the secondary and normal hydrogen to reach thermodynamic equilibrium. In some embodiments, secondary hydrogen can be increasingly populated at low temperatures. In some alternative embodiments, liquid secondary hydrogen can be prepared similarly. Consistent with the disclosed embodiments, secondary hydrogen can be generated in advance or as needed.

[0044] Consistent with the disclosed embodiments, optional step 103 of process 100 describes the transport of pressurized secondary hydrogen containers (e.g., gas cylinders). These secondary hydrogen containers can be filled and transported near an MRI scanner. In some alternative embodiments, the pressurized secondary hydrogen can be a liquid secondary hydrogen cylinder, which can also be filled and transported. In alternative embodiments, the secondary hydrogen generator is connected to a PHIP polarizer, thus reducing the need for secondary hydrogen gas containers.

[0045] Consistent with the disclosed embodiments, step 105 of process 100 describes the secondary hydrogenation of the precursor. In some embodiments, secondary hydrogen may be combined with the precursor (e.g., in a solution or mixture) to hydrogenate the precursor and produce I. z1 I z2 , the low-energy states between |↑>|↓> and |↓>|↑> or the singlet spin stages on two hydrogen spins.

[0046] Consistent with the disclosed embodiments, step 107 describes the transfer of population difference in the spin state of the secondary hydride proton to polarization on the target nucleus spin of the secondary hydride precursor. Consistent with the disclosed embodiments, such transfer can be achieved using at least one of modulation of a magnetic field applied to a solution containing the secondary hydride precursor or application of a radio frequency pulse sequence. Such transfer can produce a hyperpolarized precursor. In some embodiments, the precursor to be hydrogenated and hyperpolarized may include side arms (e.g., the precursor may be an ester of the target compound). The hydrogenation reaction can occur in the side arms, and the spin level can be transferred to polarization on the target nucleus spin at a location in the target compound.

[0047] Consistent with the disclosed embodiments, step 109 describes the purification or separation of the pristine solution of the hyperpolarization precursor (or the hyperpolarization target compound derived from the hyperpolarization precursor). In some embodiments using PHIP-SAH, purification or separation may involve cleaving the hyperpolarization precursor to produce the hyperpolarization target compound. In embodiments using PHIP or SABRE, the hyperpolarization precursor may include the hyperpolarization target compound. Purification or separation may involve inducing precipitation of the hyperpolarization precursor or hyperpolarization target compound from the pristine solution.

[0048] Consistent with the disclosed embodiments, optional step 111 describes the transport of the precipitate. The precipitate may be transported in a transport device having a magnetic field and optionally a coolant.

[0049] Consistent with the disclosed embodiments, optional step 113 describes the use of the target compound. In some embodiments, after the precipitated particles are redissolved (and optionally after temperature and pH adjustment; cleavage of the precursor and separation of the target compound; or any other chemical reaction), the hyperpolarized target compound can be injected into a patient for MRI imaging (e.g., hyperpolarized MRI experiments, or another suitable imaging action).

[0050] target compounds

[0051] In some embodiments, the target compound can be selected such that, after hydrogenation and other potential chemical reactions, one of the products is a hyperpolarized target compound suitable for HP MRI applications, such as a hyperpolarized biorelevant imaging agent. In some embodiments, the hyperpolarized target compound can be generated by additional chemical reactions. Such additional chemical reactions may involve adding a side arm containing an unsaturated moiety for hydrogenation and polarization to transfer polarization to the target compound, followed by cleaving the side arm, for example, by hydrolysis. For example, an ester of the target compound can be used for polarization using the PHIP-SAH method. In the PHIP-SAH method, a precursor, a chemical derivative of the target compound, such as a biorelevant imaging agent, is hydrogenated by secondary hydrogenation. The chemical derivative typically comprises an ester containing a biorelevant imaging agent and a side arm containing an unsaturated carbon-carbon bond. The secondary hydrogenation is used to hydrogenate the unsaturated carbon-carbon bond and transfer the spin order from the secondary hydrogenation to the target compound. After hydrogenation and polarization transfer, the ester can be cleaved to produce the hyperpolarized target compound. In some embodiments, various precursors and esters of the target compound can be used. In some embodiments, the ester is an enol or alkynol ester of a carboxylic acid; in other embodiments, it is an ester such as allyl and propargyl esters. Various embodiments of this disclosure disclose methods for extracting spin stages from side arms. 1 H spin transfers to the nuclear spin of the sidearm or the target compound itself. In some embodiments, polarization can be hyperpolarization (HP), which refers to an excess population in one or more nuclear spin states compared to the thermal equilibrium nuclear spin state distribution in a given magnetic field. Such a thermal equilibrium distribution can be described by the Boltzmann distribution.

[0052] In some embodiments, the spin level may first transfer from the spin level on secondary hydrogen to the spin level or polarization on the first nuclear spin in the sidearm, and from there to the second nuclear spin in the target compound. For example, the first nuclear spin may be in the sidearm 1 The H nuclear spin, and the second nuclear spin can be in the target compound. 13 C-nuclear spin, or alternatively, in the side arm 13 C or 15 The N spin then transfers to the target compound. 13 C or 15 N spin. In some implementations, even for triple bond distance, 13 C- 13 CJ coupling can still be greater than 1 Hz, and in a preferred embodiment, further [the target compound is used]. 13 The C nucleus spin can be hyperpolarized. For example, this allows the spin from the side arms to be hyperpolarized. 13 The polarization of [2-13C]pyruvate is achieved by C spin shift.

[0053] Various embodiments of this disclosure disclose the use of secondary hydrogen to hydrogenate the side arms of a target compound.

[0054] In some embodiments, the precursor may be selected such that, following hydrogenation and other potential chemical reactions, one of the products is a target compound suitable for HP MRI applications. In some embodiments, the target compound may be generated by further chemical reactions following hydrogenation. Such further chemical reactions may involve adding a side arm containing an unsaturated moiety for hydrogenation and polarization to transfer polarization to the target compound, and then cleaving the side arm of the target compound, for example, by hydrolysis. For example, an ester of the target compound may be used for polarization using the PHIP-SAH method. After hydrogenation and polarization transfer, the ester may be hydrolyzed to produce a hyperpolarized target compound.

[0055] As used in this article, hydrolysis is defined as the cleavage of a molecule via nucleophilic substitution in the presence of water. It can also occur under anhydrous conditions in the presence of hydroxide ions.

[0056] In some embodiments, a carboxylic acid having the following general formula (I) can be used as a target compound:

[0057]

[0058] in

[0059] -C * This indicates that the carbon atoms of the carboxylic acid ester have undergone 13C hyperpolarization.

[0060] -R is a straight-chain, branched, or cyclic alkyl chain, optionally selected from carbonyl (C=O), hydroxyl (C–OH), or amino (NR). 1 R 2 The halogen atom and one or more groups in the haloalkyl group are interrupted or substituted, or substituted by a carbocyclic aliphatic or aromatic ring, which is optionally substituted by one or more functional groups.

[0061] In some embodiments, the precursor of the target compound may be an unsaturated ester of the target compound. In some embodiments, the unsaturated bonds in the target compound may be at least 3 bonds away from the target spin. In some embodiments, the target spin is C of formula (I). * Atoms and molecules. In some embodiments after hydrogenation, the secondary hydride proton is at least four bonds away from the target atom.

[0062] Using a secondary hydride proton at least four bonds away from the target atom can reduce the trade-offs that may occur when using a secondary hydride proton with fewer bonds. For example, using a pyruvate side arm confined to three or fewer bonds between the secondary hydride proton and the target nucleus leads to a trade-off between precursor stability, hydrogenatability, and synthesability. For instance, when confined to three or fewer bonds, it is possible to formulate a more stable precursor that is more difficult to hydrogenate, or a less stable precursor that is easier to hydrogenate. In both cases, the synthesis of the precursor can be difficult. Increasing the number of bonds between the secondary hydride proton and the target atom can reduce these trade-offs because the formulation of the precursor is less restricted. Therefore, precursors that are easier to hydrogenate and easier to synthesize can be formulated. However, the polarization transfer between the secondary hydride proton and the target atom may become more difficult. Polarization transfer can be particularly difficult when using RF pulses and magnetic fields with amplitudes between 0 mT and 500 mT, because proton resonance frequencies can be difficult to distinguish at such magnetic field amplitudes (i.e., the J-coupling between protons can be greater than their Larmor frequency difference). The disclosed embodiments address this problem using mediated protons that form a quantum three-body system with secondary hydride protons. Spin stages can be transferred from secondary hydride protons to target atoms in the target compound via mediated protons. Therefore, acceptable levels of polarization transfer can be obtained, and the benefit of greater separation between the secondary hydride protons and the target compound is realized.

[0063] In some embodiments, the precursor molecule structure is given by formula (II) or formula (III). Formula (II) shows the general structure of the propyl ester and allyl ester of the target carboxylic acid compound of formula (III), wherein the unsaturated bond is three bonds away from the target spin. After hydrogenation of the unsaturated bond with a secondary hydrogen, the secondary hydrogenated proton is four and five bonds away from the target spin, respectively. In some embodiments, the mediating proton can be used to generate polarization transfer with a polarization transfer waveform to the 13C enriched site:

[0064]

[0065] in

[0066] -C * This refers to naturally occurring 13C-enriched or optionally 13C-labeled carboxylic acid ester carbon atoms that have undergone 13C hyperpolarization.

[0067] -R is defined above for equation (I).

[0068] -R 3 It is H (containing isotopes) 1 H and 2H), a straight-chain, branched, or cyclic hydrocarbon chain, which is optionally interrupted or substituted by one or more functional groups, halogen atoms, and haloalkyl groups, or substituted by carbocyclic aliphatic or aromatic rings, which are optionally substituted by one or more functional groups or by heteroatoms (e.g., N, O, Si, P, S, halogens, etc.).

[0069] -R 4 It is H (containing isotopes) 1 H and 2 H), a straight-chain, branched, or cyclic hydrocarbon chain, which is optionally interrupted or substituted by one or more functional groups, halogen atoms, and haloalkyl groups, or substituted by carbocyclic aliphatic or aromatic rings, which are optionally substituted by one or more functional groups or by heteroatoms (e.g., N, O, Si, P, S, halogens, etc.).

[0070] -R 5 It is H (containing isotopes) 1 H and 2 H), a straight-chain, branched, or cyclic hydrocarbon chain, which is optionally interrupted or substituted by one or more functional groups, halogen atoms, and haloalkyl groups, or substituted by carbocyclic aliphatic or aromatic rings, which are optionally substituted by one or more functional groups or by heteroatoms (e.g., N, O, Si, P, S, halogens, etc.).

[0071] -R 6 It is H (containing isotopes) 1 H and 2 H), a straight-chain, branched, or cyclic hydrocarbon chain, which is optionally interrupted or substituted by one or more functional groups, halogen atoms, and haloalkyl groups, or substituted by carbocyclic aliphatic or aromatic rings, which are optionally substituted by one or more functional groups or by heteroatoms (e.g., N, O, Si, P, S, halogens, etc.).

[0072] -R 7 It is H (containing isotopes) 1 H and 2 H), a straight-chain, branched, or cyclic hydrocarbon chain, which is optionally interrupted or substituted by one or more functional groups, halogen atoms, and haloalkyl groups, or substituted by carbocyclic aliphatic or aromatic rings, which are optionally substituted by one or more functional groups or by heteroatoms (e.g., N, O, Si, P, S, halogens, etc.).

[0073] parahydrogenation

[0074] Consistent with the disclosed embodiments, the precursor of the target compound can be secondary hydrogenated by combining the precursor, secondary hydrogen, and a hydrogenation catalyst. The disclosed embodiments are not limited to specific methods for producing secondary hydrogenated precursors. In some embodiments, the precursor can be added to a mixture containing secondary hydrogen. In some embodiments, secondary hydrogen gas can be added to a solution containing the precursor (e.g., the secondary hydrogen gas can be bubbled into such a solution). During the hydrogenation of the precursor, the secondary hydrogen can generate I... z1 I z2 The lower energy states between the two hydrogen spins in the precursor are preferentially populated.

[0075] The precursor may have unsaturated bonds, which can be hydrogenated by secondary hydrogen. After the precursor is combined with secondary hydrogen, more than about 50%, more than about 60%, more than about 70%, more than about 80%, more than about 90%, or almost all of the precursor can be hydrogenated. Similarly, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, or less of the precursor can be hydrogenated. Alternatively, the percentage of hydrogenation can be within the range defined by any two of the foregoing values.

[0076] In some embodiments, the secondary hydrogenation precursor may have a population of at least 10%, 20%, or 40% in the secondary hydrogenation proton spin state. In some embodiments, the population exists between spin states that include the secondary hydrogenation proton as well as other nuclear spins, such as additional protons on the compound. In some embodiments, the secondary hydrogenation precursor may include a sidearm, and the secondary hydrogenation spin may be located on the sidearm.

[0077] In some embodiments, the concentration of the hydrogenation catalyst during hydrogenation can be up to about 50 mM, 40 mM, 30 mM, 20 mM, 10 mM, 9 mM, 8 mM, 7 mM, 6 mM, 5 mM, 4 mM, 3 mM, 2 mM, 1 mM, 0.9 mM, 0.8 mM, 0.7 mM, 0.6 mM, 0.5 mM, 0.4 mM, 0.3 mM, 0.2 mM, 0.1 mM, or less. At least about 0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 20mM, 30mM, 40mM, 50mM or more; or within the range defined by any two of the foregoing values.

[0078] The disclosed embodiments may include a method for generating a hyperpolarized target compound implemented by the disclosed system. The disclosed method may include mixing a solution containing a precursor of the target compound and a hydrogenation catalyst via a mixing mechanism. The mixing mechanism may be a device for introducing, holding, and promoting blends, mixtures, or solutions of two or more materials. In some embodiments, the mixing mechanism may be located in a chamber, and mixing may occur inside the chamber. In some embodiments, the solution may be mixed at a location remote from the chamber. The volume of the solution may be at least about 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 20 ml, 30 ml, 40 ml, 50 ml, 60 ml, 70 ml, 80 ml, 90 ml, 100 ml or more; or the volume may be at most 100 ml, 90 ml, 80 ml, 70 ml, 60 ml, 50 ml, 40 ml, 30 ml, 20 ml, 10 ml, 9 ml, 8 ml, 7 ml, 6 ml, 5 ml, 4 ml, 3 ml, 2 ml, 1 ml or less; or within the volume range defined by any two of the foregoing values.

[0079] In some embodiments, the mixing mechanism may be a gas-liquid exchange mechanism. For example, a gas-liquid exchange mechanism may be a bubbler or a diffusion system. In some embodiments, the mixing mechanism may include a membrane adapted to allow molecular hydrogen diffusion. In some embodiments, mixing may be carried out using a spray chamber, wherein a solution is sprayed into a chamber filled with pressurized secondary hydrogen.

[0080] In some embodiments, the catalyst can be any molecular, complex, or particulate system that catalyzes hydrogenation. In some embodiments, homogeneous metal catalysts, such as rhodium or ruthenium complexes, can be provided. Rhodium complexes can be used for coordination and activation of precursor molecules and secondary hydrogens. In some embodiments, heterogeneous metal catalysts linked to nanoparticles can be used.

[0081] Various embodiments of this disclosure disclose introducing a solution into a chamber configured to hold the solution during polarization transfer. In some embodiments, the solution may be mixed within the chamber. In some embodiments, the solution may be hydrogenated within the chamber. In some embodiments, the chamber may be within a magnetic shield (e.g., a μ-metal shield). Magnetic shielding can reduce the influence of the Earth's magnetic field (or other external magnetic fields). Therefore, placing the solution within the chamber may involve placing the solution within a magnetic shield. In some embodiments, a magnetic field generator, such as an electromagnet or permanent magnet, may be configured to generate a magnetic field within the chamber. An RF coil may be configured to generate RF irradiation within the chamber for inducing polarization transfer.

[0082] As described herein, in some embodiments, secondary hydrogenation may occur prior to polarization transfer (e.g., before RF irradiation is applied to the solution, etc.). In various embodiments, secondary hydrogenation may occur during polarization transfer. For example, during modulation of the magnetic field amplitude, secondary hydrogen may combine with the solution (e.g., flowing through or bubbling through the solution).

[0083] In some embodiments, secondary hydrogen can be combined with a solution in a hydrogenation chamber under pressure. The pressure can be at least about 10 bar, 15 bar, 20 bar, 30 bar, 50 bar or greater; the pressure can be at most about 50 bar, 30 bar, 20 bar, 15 bar, 10 bar or less; or the pressure can be within the range defined by any two of the foregoing values. In such embodiments, secondary hydrogen can be combined with a solution in a pressure-resistant metal chamber. Secondary hydrogen can be combined with a solution at time intervals (or the dissolution of secondary hydrogen can occur within a time interval). The time interval can be less than about 90 seconds, 60 seconds, 30 seconds, 20 seconds, 10 seconds, 5 seconds, 3 seconds or less; the time interval can be greater than about 3 seconds, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 60 seconds, 90 seconds or more; or the time interval can be within the range defined by any two of the foregoing values.

[0084] The envisioned system and method can be used with any suitable polarization transfer scheme that uses secondary hydrogen-induced polarization (e.g., PHIP, PHIP-SAH, SABRE, or any other suitable polarization transfer method).

[0085] When used with SABRE, both the secondary hydrogen molecule and the target compound can bind to the polarization transfer catalyst. Polarization transfer can then occur at least partially when the secondary hydrogen and the target compound bind. In some embodiments, the secondary hydrogen gas is dissolved in a first solution containing the target compound and the polarization transfer catalyst. The first solution can be any solvent capable of SABRE polarization, including aqueous solutions or organic solvents such as deuterated chloroform, deuterated acetone, deuterated ethanol, or deuterated methanol.

[0086] In such embodiments, the polarization transfer catalyst can reversibly combine with the target compound (e.g., pyridine or another suitable target compound) and secondary hydrogen, enabling spin-level or polarization transfer to the target compound. Following such transfer, the average polarization of the compound is at least about 1%, 10%, 30%, or 50%; at most about 90%, 50%, 30%, 10%, or 1%; or within the range defined by any two of the foregoing values. The type of polarization nucleus can be... 15 N、 13 C 1 H, 31 P, 19 F or other nuclei that can be polarized by SABRE.

[0087] In some embodiments, the polarization transfer catalyst may be or comprise a metal complex, such as an iridium organometallic complex (e.g., an iridium organometallic complex [IrCl(COD)(1,3-bis(2,4,6-trimethylphenyl)imidazol-2-yl)]). In some embodiments, the polarization transfer catalyst may be or comprise a heterogeneous metal catalyst linked to nanoparticles.

[0088] polarization transfer

[0089] In some embodiments, prior to polarization transfer, the concentration of the precursor (in embodiments using PHIP-SAH) or the target compound (in embodiments using PHIP or SABRE) in solution may be greater than about 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 250 mM, 400 mM, 600 mM, 1000 mM, or greater. In some embodiments, the concentration of the precursor may be less than about 1000 mM, 600 mM, 400 mM, 250 mM, 100 mM, 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 20 mM, 10 mM, or less. The volume of the solution can be greater than about 1 ml, 2 ml, 3 ml, 5 ml, 10 ml, 20 ml, 30 ml, 50 ml, 100 ml, 200 ml, 300 ml, 500 ml, 1000 ml, 2000 ml or more; less than 2000 ml, 1000 ml, 500 ml, 300 ml, 200 ml, 100 ml, 50 ml, 30 ml, 20 ml, 10 ml, 5 ml, 3 ml, 2 ml, 1 ml or less; or within the range defined by any two of the foregoing values.

[0090] Using radio frequency waveform transfer polarization

[0091] Various embodiments of this disclosure disclose the application of polarization-transfer magnetic perturbation for generating a magnetic field around a solution. In some embodiments, the strength of the magnetic field is at least about 0 G, 0.01 G, 0.02 G, 0.03 G, 0.04 G, 0.05 G, 0.06 G, 0.07 G, 0.08 G, 0.09 G, 0.1 G, 0.2 G, 0.3 G, 0.4 G, 0.5 G, 0.6 G, 0.7 G, 0.8 G, 0.9 G, 1 G, 2 G, 3 G, 4 G, 5 G, 6 G, 7 G, 8 G, 9 G, 10 G, 20 G, 30 G, 40 G, 50 G, 60 G, 70 G, 80 G, 90 G, 100 G, 200 G, 300 G, 400 G, 500 G, 600 G, or 700 G. 800G, 900G, 1,000G, 2,000G, 3,000G or greater; or up to about 3,000G, 2,000G, 1,000G, 900G, 800G, 700G, 600G, 500G, 400G, 300G, 200G, 100G, 90G, 80G, 70G, 60G, 50G, 40G, 30G, 20G, 10G, 9G, 8G, 7G, 6G, 5G, 4G, 3G, 2G, 1G, 0.9G, 0.8G, 0.7G, 0.6G, 0.5G, 0.4G, 0.3G, 0.2G, 0.1G or less. In some embodiments, the strength of the magnetic field is within the range defined by any two of the foregoing values. For example, in some embodiments, the magnetic field strength around the solution is from 0.1 G to 3,000 G. In some embodiments, the magnetic field strength is from 0 G to 0.1 G. Magnetic disturbance can be generated by magnetic shielding, coils, electromagnets, or permanent magnets, or combinations thereof. The magnetic field can be applied to the sample in the form of pulsed or continuous wave (CW). The magnetic disturbance can be static or time-varying.

[0092] A signal generator can be configured to generate one or more radio frequency (RF) waveforms, which can be applied to a sample to transfer polarization. The signal generator can include multiple computing units, processors, controllers, associated memory, PCs, computer services, or any device capable of performing computational operations on inputs and generating outputs. In some embodiments, an RF coil can radiate or 'apply' an RF irradiation or pulse sequence containing a first RF waveform. In some embodiments, the RF coil can have one or more channels. A channel can be a path for an RF signal. At least one channel can be provided for each different type of NMR spectroscopy. In some embodiments, there can be a path for... 1 At least one channel of H and for 13 At least one channel of C. The first RF waveform can be applied to one or more RF coils (RF coils) positioned around the sample. 1H channel. In some embodiments, a second RF waveform can be applied to the RF coil. 13 C-channel. In some embodiments, 13 The RF waveform on the C channel can be configured to apply polarization transfer sequences such as gS2hm, S2hM, SLIC, ADAPT, or PulsePol.

[0093] In some embodiments, the pulse sequence can be configured to start from an equivalent 1 H-hydrogen spin-shift spin order, for example, when the chemical shift difference is less than the J coupling between them. Examples of such sequences can be Goldman sequences (Goldman, H. Jóhannesson, *Physical Reports (CRPhys.)* 2005, 6, 575–581, references which are incorporated herein by reference in full for all purposes), singlet-to-heteronuclear magnetization (S2hM) sequences, pulsed polarization (PulsePol) sequences, or other sequences used in singlet NMR (e.g., ADAPT, SLIC, etc.). For hydride protons in symmetric molecules independent of magnetic fields, or for hydride protons in many molecular esters in various magnetic fields, equivalent sequences may occur. 1 H hydrogen spin (e.g., when the chemical shift difference is less than the J coupling between them). For example, equivalent 1 The hydrogen spin can exist at least 0.01 mT, 0.1 mT, 0.2 mT, 0.3 mT, 0.4 mT, 0.5 mT, 0.6 mT, 0.7 mT, 0.8 mT, 0.9 mT, 1 mT, 2 mT, 3 mT, 4 mT, 5 mT, 6 mT, 7 mT, 8 mT, 9 mT, 10 mT, 20 mT, 30 mT, 40 mT, 50 mT, 60 mT, 70 mT, 80 mT, 90 mT, 100 mT or greater; and at most 10 mT. In magnetic fields of 0 mT, 90 mT, 80 mT, 70 mT, 60 mT, 50 mT, 40 mT, 30 mT, 20 mT, 10 mT, 9 mT, 8 mT, 7 mT, 6 mT, 5 mT, 4 mT, 3 mT, 2 mT, 1 mT, 0.9 mT, 0.8 mT, 0.7 mT, 0.6 mT, 0.5 mT, 0.4 mT, 0.3 mT, 0.2 mT, 0.1 mT or less; or within the range defined by any two of the aforementioned values.

[0094] In some embodiments, the RF amplitude is between 1 Hz and 100 kHz for 13C spin precession in a rotating coordinate system. In some embodiments, the RF frequency is between 20 Hz and 200 kHz, or between 1 Hz and 1 MHz.

[0095] In some embodiments, the strength of the magnetic field is between 0 G and 0.1 G. In some embodiments, within this magnetic field range, the applied RF field amplitude is greater than the static magnetic field amplitude. The Hamiltonian can be represented using a reference coordinate system rotated with the RF field frequency. The resulting Hamiltonian can have the following form. Where B1 is the amplitude of the RF field, γ H γ X It is the gyromagnetic ratio of the proton spin to the target spin (for simplicity, the equation assumes no other non-proton spins, but the Hamiltonian can be easily modified to include other spins).<i,j> Let (i,j) be the sums on the same and different nuclei, respectively. It can be assumed that the constant magnetic field is negligible in the rotating coordinate system. The Hamiltonian generated in the rotating coordinate system is analogous to the standard Hamiltonian in a constant magnetic field in the laboratory coordinate system without a driving field. Therefore, many polarization transfer schemes developed for these systems, such as magnetic field modulation, pulse sequences like S2hM, PulsePol, CW irradiation (e.g., SLIC), and amplitude modulation, can be used only in the rotating coordinate system, not in the laboratory coordinate system. To add an additional driving field in the rotating coordinate system, the frequency of the first driving field must be considered, for example, applying cosω1t cosω2tI. y This will result in an oscillating field with a frequency of ω2 in the rotating coordinate system.

[0096] In some embodiments, the magnetic shield can be configured to maintain the uniformity of the magnetic field or generate a magnetic field lower than the Earth's magnetic field (ranging from approximately 0.25 G to 0.65 G, depending on the location). The magnetic shield can maintain the magnetic field strength within the polarization chamber during the application of a polarization waveform to one or more radio frequency coils.

[0097] Consistent with the disclosed embodiments, when performing PHIP or PHIP-SAH polarization, an RF waveform can be applied to a solution containing a secondary hydrogenation precursor or a secondary hydrogenation target compound. When performing SABRE polarization, an RF waveform can be applied to a solution containing a target compound, secondary hydrogen, and a polarization transfer catalyst. The concentrations of the target compound, secondary hydrogen, and polarization transfer catalyst can be as given herein.

[0098] The polarization waveform can generate an RF field on or within the volume of the polarization transfer chamber 402. This volume can be greater than approximately 1 ml, 2 ml, 3 ml, 5 ml, 10 ml, 20 ml, 30 ml, 50 ml, 100 ml, 200 ml, 300 ml, 500 ml, 1000 ml, 2000 ml or larger; or less than 2000 ml, 1000 ml, 500 ml, 300 ml, 200 ml, 100 ml, 50 ml, 30 ml, 20 ml, 10 ml, 5 ml, 3 ml, 2 ml, 1 ml or smaller; or within the range defined by any two of the foregoing values. RF field modulation can be performed over a duration. The duration can be greater than approximately 100 milliseconds, 200 milliseconds, 300 milliseconds, 500 milliseconds, 1000 milliseconds, 2000 milliseconds, 3000 milliseconds, 5000 milliseconds, 10000 milliseconds, 20000 milliseconds, 30000 milliseconds, or longer; or less than approximately 30000 milliseconds, 20000 milliseconds, 10000 milliseconds, 5000 milliseconds, 3000 milliseconds, 2000 milliseconds, 1000 milliseconds, 500 milliseconds, 300 milliseconds, 200 milliseconds, 100 milliseconds, or shorter; or within the range defined by any two of the foregoing values. In some embodiments, the RF amplitude adiabatically sweeps across the resonance condition, where the frequency is the open or closed resonance of the target spin Larmor frequency.

[0099] In some embodiments, after the polarization transfer step, the non-hydrogen nuclear spin polarization of the bioassociated imaging agent is greater than about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or greater; the nuclear spin polarization is 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less; or the nuclear spin polarization is within the range defined by any two of the foregoing values. In some embodiments, this polarization is achieved for the following volumes: greater than about 5 ml, 10 ml, 20 ml, 30 ml, 40 ml, 50 ml, 60 ml, 70 ml, 80 ml, 90 ml, 100 ml, 200 ml, 300 ml, 400 ml, 500 ml, 600 ml, 700 ml, 800 ml, 900 ml, 1000 ml or greater; or 1000 ml, 900 ml, 800 ml, 700 ml, 600 ml, 500 ml, 400 ml, 300 ml, 200 ml, 100 ml, 90 ml, 80 ml, 70 ml, 60 ml, 50 ml, 40 ml, 30 ml, 20 ml, 10 ml, 5 ml or less; or within the range defined by any two of the foregoing values.

[0100] In some embodiments, certain components on the precursor molecule 1 The H spin is deuterated (i.e.,1 H spin was 2 H-spin substitution). In the low-field state where the polarization transfer described in this paper occurs, due to the difference in Larmor frequencies, 2 The presence of H spin is only related to secondary hydrogenation. 1 H spin or mediated by ZZ interaction 1 H spin coupling, and therefore does not significantly affect polarization transfer.

[0101] In some embodiments, the precursor molecule is an ester of the target compound polarized by the PHIP-SAH method. In many cases, keeping the unsaturated bonds at least four bonds away from the target nucleus enables a more robust and stable precursor molecule. In some embodiments, both secondary hydride protons on the side arms are at least four bonds away from the target nucleus. In some embodiments, the polarization transfer from the secondary hydride protons to the target nucleus spin is accomplished using RF irradiation in an equivalent state. In some embodiments, the direct coupling between the secondary hydride protons and the target nucleus spin is less than 0.5 Hz, 0.3 Hz, 0.1 Hz, or 0.05 Hz, and the proton spin is mediated to generate a larger effective coupling.

[0102] Compared to high-field states (i.e., states where the chemical shifts are greater than the J-coupling between secondary hydride protons), where the proton chemical shifts allow for spectral differentiation of different protons, using equivalent states mediated by proton spin is challenging due to several issues: (1) protons cannot be individually addressed; (2) in equivalent states, due to the indistinguishability of proton spins, the initial singlet states are distributed between coupled proton spins and, unlike high-field states, are not limited to secondary hydride spins; and (3) the coupling between mediated spins and secondary hydride spins is a completely long-term coupling, unlike the zz-coupling in high-field states. This makes it impractical to first transfer the polarization to the mediated spin sequence.

[0103] In some embodiments, proton spin is mediated in the equivalent state to transfer polarization to the target (e.g., 13 C 15 (N, etc.) nuclear spin.

[0104] In some embodiments, some of the secondary hydrogenation precursor molecules or target compounds 1 The H nucleus spin is deuterated (i.e., some H nuclei spin is deuterated). 1 H nucleus spin was 2 H nuclear spin substitution). In the low-field state where the polarization transfer described in this paper occurs, due to the difference in Larmor frequencies, 2 The presence of H spin is only related to secondary hydrogenation. 1 H spin or mediated by ZZ interaction 1 H spin coupling, and therefore does not significantly affect polarization transfer.

[0105] Using spin-mediated polarization transfer in the equivalent state

[0106] In some embodiments, polarization can be shifted from RF pulse sequences, CW irradiation, or modulation of the magnetic field amplitude or frequency using modulation. 1 The spin of the secondary hydride is transferred to the spin of the target atom. This occurs when the spin of the secondary hydride proton (e.g., located on the side arm of the secondary hydride precursor) is transferred to the spin of the target atom (e.g., located in the target compound). 13 When the J-coupling between spins of C atoms is too weak for direct polarization transfer, mediated nuclear spins can be used to achieve polarization transfer.

[0107] The effectiveness of using spin-mediated polarization transfer can depend on the strength of the ambient magnetic field in which the polarization transfer occurs. The chemical shift difference between spins can increase with increasing field strength. Therefore, in an “equivalent state” with low magnetic field strength, the J-coupling and chemical shift difference between spins can be quite significant. In such an equivalent state, protons may not be individually addressable. Furthermore, the initial singlet state can be distributed between coupled proton spins, rather than being limited to secondary hydride spins (e.g., due to the indistinguishability of proton spins). Additionally, the coupling between the spin-mediated and secondary hydride spins can be a fully long-term coupling (e.g., compared to only Z-coupling in higher magnetic field states). Such characteristics can lead to impractical polarization transfers using spin-mediated polarization transfer.

[0108] The upper limit of the equivalent state can depend on the compound in which polarization transfer occurs. For example, when the polarization transfer involves the secondary hydrogenated side arm of an ester (e.g., esters as described herein), the upper limit can be from 0 mT to 500 mT. The upper limit for symmetrical molecules (such as fumarates and succinates) can be even higher (e.g., >500 mT), where there is a minimal chemical shift difference between the spins of the hydrogenated protons. Therefore, a very large magnetic field may be required to avoid operating in the equivalent state.

[0109] The disclosed embodiments include methods for achieving polarization transfer using mediated nuclear spin in an equivalent state. Such methods can utilize RF pulse sequences (e.g., PulsePol, S2hM, etc.) or CW irradiation (e.g., SLIC or a target combined with amplitude sweeping). 13 (e.g., irradiation at the resonant frequency of C spin) to achieve the target (e.g.) 13 C 15 N、 19 F or 31 P) Polarization transfer of nuclear spin. Because this type of method operates in an equivalent state, it does not require the large magnetic field required by methods that do not operate in an equivalent state. Therefore, this type of method can be more easily implemented in clinical practice and on a clinical scale.

[0110] In some embodiments, an RF sweep (e.g., a magnetic resonance pulse sequence) may be applied to a compound (e.g., a solution containing a secondary hydrogenated precursor of the target compound). The RF sweep may be configured to transfer the population from the first and second protons to the target atom, thereby imparting at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom.

[0111] Figures 6B to 6D Frequency and amplitude characteristics suitable for using radio frequency sweeps mediated by proton transfer polarization, consistent with the disclosed embodiments, are described. For example... Figures 6B to 6D The described RF sweep can consist of two phases. During the first phase, the RF amplitude can increase linearly from zero, such as... Figure 6B As depicted, the frequency is maintained at the target frequency (e.g., the target atom's frequency). 13 C-Ramore frequency), such as Figure 6C As depicted. In some embodiments, the magnitude increase can be substantially linear (e.g., the increase can include temporary pauses, gradual increases, or follow a trajectory that deviates from the linear increase by less than 5% or less than 10% of the full-scale increase at any given point). In some embodiments, the magnitude increase can be substantially monotonic (e.g., the increase can follow a trajectory that includes temporary decreases but deviates from the monotonic increase by less than 5% or less than 10% of the full-scale increase at any given point). In some embodiments, a numerical optimizer such as GRAPE or CRAB can be used to optimize the magnitude trajectory.

[0112] During the second phase, the RF amplitude may decrease linearly to zero, while the frequency of the RF field increases linearly. In some embodiments, the frequency increase may be substantially linear (e.g., the increase may include temporary pauses, gradual increases, or follow a trajectory that deviates from the linear increase by less than 5% or less than 10% of the full-scale increase at any given point). In some embodiments, the frequency increase may be substantially monotonic (e.g., the increase may follow a trajectory that includes temporary decreases, but deviates from the monotonic increase by less than 5% or less than 10% of the full-scale increase at any given point).

[0113] Figure 6E The description is consistent with the disclosed embodiments, and is based on... Figures 6B to 6D During the application of radio frequency sweeping, in planes transverse and parallel to the static magnetic field 13 C polarization. For example... Figure 6E As shown, during the first stage (e.g., first stage 681), polarization (e.g., spin class) can be transferred from secondary hydride protons (e.g., double bond addition through unsaturated precursors) via a proton spin network. 13 C core. This process can lead to... 13The accumulation of C-polarization, which accumulates in a plane transverse to the static magnetic field (e.g., along the x-axis, y-axis, or other locations in the xy-plane), as depicted by trace 685. During a second phase (e.g., second phase 687), the polarization can be adiabatically transferred from the xy-plane to the z-axis (as depicted by trace 685). In some embodiments, ensuring 13 C polarization parallel to a static magnetic field (e.g., along the z-axis) can facilitate the transport of polarization precursors (or polarization target compounds).

[0114] RF sweeping can be performed while applying a magnetic field to the compound. In some embodiments, the average magnetic field strength may be greater than at least 0.01 mT, 0.02 mT, 0.05 mT, 0.1 mT, 0.2 mT, 0.5 mT, 1 mT, 2 mT, 5 mT, 10 mT, 20 mT, 50 mT, 100 mT, 200 mT, 500 mT, 1,000 mT, 2,000 mT, 5,000 mT or greater; or at most about 5,000 mT, 2,000 mT, 1,000 mT, 500 mT, 200 mT, 100 mT, 50 mT, 20 mT, 10 mT, 5 mT, 2 mT, 1 mT, 0.5 mT, 0.2 mT, 0.1 mT, 0.05 mT, 0.02 mT, 0.01 mT or less; or be an average magnetic field strength within the range defined by any two of the foregoing values.

[0115] In some embodiments, the first of the secondary hydride protons may have a first Larmor frequency determined by the average magnetic field strength, the second of the secondary hydride protons may have a second Larmor frequency determined by the average magnetic field strength, and the mediating proton may have a third Larmor frequency determined by the average magnetic field strength. These three Larmor frequencies may be different. In some embodiments, the first difference between the first and second Larmor frequencies, the second difference between the first and third Larmor frequencies, or the third difference between the second and third Larmor frequencies is less than the first J-coupling (J... 12 Twice that of the second J-coupling (J) 23 ) twice or third J coupling (J 3c Twice that of the first difference, the second difference, or the third difference. In some embodiments, at least one of the first difference, the second difference, or the third difference is less than 20 Hz.

[0116] In some embodiments, magnetic field sweeping can be used to transfer polarization. Magnetic field sweeping may include first, second, and third stages. In the first stage, a constant magnetic field is applied. In the second stage, the strength of the magnetic field can be reduced to a low value. In the third stage, the strength of the magnetic field can be increased. The increase can be incremental or linear.

[0117] Figure 2AA quantum mechanical four-body system suitable for using mediated proton transfer polarization, consistent with the disclosed embodiments, is depicted. This system comprises two secondary hydride spins (spin 1 and spin 2, with J-coupling). 12 A mediated proton spin (spin 3, assuming coupling with spin 1 and J coupling with spin 2). 23 (negligible) and target 13 C-nuclear spin (spin C). The coupling between spins that only cause tiny changes in intrinsic energy (e.g., spin 3 to spin 1 coupling, spin 1 to spin C coupling, etc.) is omitted. Figure 2A A typical arrangement may contain three secondary hydrogenated precursor molecules. 1 H atom and a 13 C atoms. Three 1 A hydrogen atom can contain two atoms bonded by three atomic bonds. 1 A separate mediator in the H atom 1 H atoms, the two 1 The H atom is the result of the unsaturated bond being hydrogenated by a secondary hydrogen molecule.

[0118] In some embodiments, two 1 Each H atom and its corresponding 12 C atoms are covalently bonded. Correspondingly... 12 Two carbon atoms can be covalently bonded to each other. In some embodiments, two... 1 The H atom can be bonded to one through at least four chemical bonds. 13 C atom separation. For example, when the cinnamon pyruvate precursor is secondary hydrogenated via a double bond, the secondary hydrogen proton is introduced into the distance. 13 The C target atom has four and five bonds. In some embodiments, 13 C atom (or other target atom) and mediator 1 H atoms are covalently bonded. In some arrangements, the atoms forming the quantum mechanical three-body system can be pyruvate, a precursor of pyruvate containing at least one unsaturated bond, fumarate, a precursor of fumarate containing at least one unsaturated bond, succinate, or a portion of a precursor of succinate containing at least one unsaturated bond.

[0119] Figure 2B The information was made public by Figure 2A The approximate energy structure of the quantum mechanical three-body system described by the protons is consistent with the disclosed embodiment. The system with three proton spins exhibits... Figure 2B The eigenstates and energy splitting described in the text. Where a = J 23 / J 12 and The four highest energy states (state 201) are defined as states 1 to 4, the two intermediate energy states (state 203) are defined as states 5 and 6, and the two lower energy states (state 205) are defined as states 7 and 8. The singlet state of the secondary hydrogenated spin is no longer an eigenstate of the system. Instead, singlet states are distributed between states 203 and 205. The population of state 205 is given by the following relation:

[0120] P(7,8)=(2-a+2s) / 4s

[0121] When J 12 >J 23 At this time, states 7 and 8 can be highly populated (e.g., in some embodiments, having a population greater than a value between 0.7 and 0.9, or in various embodiments greater than an application-dependent threshold). For example, taking J... 12 =11.4Hz, J 23 =4.9Hz, J 3C =3.15Hz, then P(7,8) = 0.928. Therefore, the quantum mechanical three-body system contains high-population energy eigenstates (e.g., states 7 and 8) and low-population energy eigenstates, allowing over 90% of the population difference between states to be transferred. Pulse sequences operable in the equivalent states (e.g., S2hM, PulsePol, or another suitable pulse sequence) can be applied. Figure 2A The general layout described in the text uses Instead of J 12 As a bandgap (the bandgap used when there is no mediating spin).

[0122] Figure 3 The embodiments consistent with those disclosed are depicted. Figure 2A Simulation and calculation of the PulsePol transfer efficiency of spin systems in J. 12 =11.4Hz, J 23 =4.9Hz, J 3C The PulsePol transfer efficiency was simulated and calculated at a coupling frequency of 3.15 Hz. Trace 301 depicts the PulsePol transfer efficiency under the resonance condition E = 3.15 Hz. Nuclear spin polarization. Trace 303 depicts the nuclear spin polarization under the resonance condition E = sJ. 12 Nuclear spin polarization with τ = π / 4E was achieved. In both simulations, nuclear spin polarization exceeding 80% was realized.

[0123] Using magnetic field modulation to transfer polarization

[0124] In some embodiments, polarization-transfer magnetic perturbation can be performed within the magnetic shield (e.g., μ-shielding) to achieve a uniform low magnetic field. The magnetic shield is capable of polarization transfer to a magnetic field of μT below the Earth's magnetic field. 13C nucleus spin. Low magnetic fields can be greater than approximately 0 mG, 0.1 mG, 0.2 mG, 0.3 mG, 0.4 mG, 0.5 mG, 0.6 mG, 0.7 mG, 0.8 mG, 0.9 mG, 1.0 mG, 2.0 mG, 3.0 mG, 4.0 mG, 5.0 mG, 6.0 mG, 7.0 mG, 8.0 mG, 9.0 mG, 10 mG, 20 mG, 30 mG, 40 mG, 50 mG, 60 mG, 70 mG, 80 mG, 90 mG, 100 mG, or... Larger; or less than approximately 100 mG, 90 mG, 80 mG, 70 mG, 60 mG, 50 mG, 40 mG, 30 mG, 20 mG, 10 mG, 9 mG, 8 mG, 7 mG, 6 mG, 5 mG, 4 mG, 3 mG, 2 mG, 1 mG, 0.9 mG, 0.8 mG, 0.7 mG, 0.6 mG, 0.5 mG, 0.4 mG, 0.3 mG, 0.2 mG, 0.1 mG or smaller; or within the range defined by any two of the foregoing values. In these fields, by utilizing proton spin and other spin types of interest (including...) 13 C 15 N、 19 F, 31 Polarization is transferred by avoiding cross-crossing (LAC) between energy levels (P). In some embodiments, the magnetic field can be tuned to a specific magnetic field strength of the LAC. In various embodiments, to achieve robust polarization transfer in a larger volume sample, the magnetic field strength can be temporally modulated. For example, the magnetic field strength can be swept across LAC conditions. Alternatively or additionally, the sample can be physically moved within the magnetic field. Such modulation can relax constraints on magnetic field homogeneity and magnetic field offset. Therefore, robust polarization transfer can be performed with larger volumes and higher efficiency. Furthermore, relaxing the restrictions on magnetic field homogeneity and magnetic field offset allows for the use of less complex, less precise, or less expensive polarization systems.

[0125] The lower limit of magnetic field modulation can be greater than approximately -10 μT, -9 μT, -8 μT, -7 μT, -6 μT, -5 μT, -4 μT, -3 μT, -2 μT, -1 μT, -0.9 μT, -0.8 μT, -0.7 μT, -0.6 μT, -0.5 μT, -0.4 μT, -0.3 μT, -0.2 μT, -0.1 μT or greater; and less than approximately -0. 1 μT, -0.2 μT, -0.3 μT, -0.4 μT, -0.5 μT, -0.6 μT, -0.7 μT, -0.8 μT, -0.9 μT, -1 μT, -2 μT, -3 μT, -4 μT, -5 μT, -6 μT, -7 μT, -8 μT, -9 μT, -10 μT or less; or within the range defined by any two of the foregoing values. The upper limit of modulation can be greater than about 0.1 μT, 0.2 μT, 0.3 μT, 0.4 μT, 0.5 μT, 0.6 μT, 0.7 μT, 0.8 μT, 0.9 μT, 1 μT, 2 μT, 3 μT, 4 μT, 5 μT, 6 μT, 7 μT, 8 μT, 9 μT, 10 μT or greater; less than about 10 μT, 9 μT, 8 μT, 7 μT, 6 μT, 5 μT, 4 μT, 3 μT, 2 μT, 1 μT, 0.9 μT, 0.8 μT, 0.7 μT, 0.6 μT, 0.5 μT, 0.4 μT, 0.3 μT, 0.2 μT, 0.1 μT or smaller; or within the range defined by any two of the aforementioned values. The magnetic field can have such amplitude over the volume of polarization transfer chamber 402 or over the volume containing the polarization transfer chamber. This volume can be greater than approximately 1 ml, 2 ml, 3 ml, 5 ml, 10 ml, 20 ml, 30 ml, 50 ml, 100 ml, 200 ml, 300 ml, 500 ml, 1000 ml, 2000 ml or larger; less than 2000 ml, 1000 ml, 500 ml, 300 ml, 200 ml, 100 ml, 50 ml, 30 ml, 20 ml, 10 ml, 5 ml, 3 ml, 2 ml, 1 ml or smaller; or within the range defined by any two of the foregoing values. Modulation can be performed over a period of time. The duration can be greater than approximately 100 milliseconds, 200 milliseconds, 300 milliseconds, 500 milliseconds, 1000 milliseconds, 2000 milliseconds, 3000 milliseconds, 5000 milliseconds, 10000 milliseconds, 20000 milliseconds, 30000 milliseconds or longer; less than approximately 30000 milliseconds, 20000 milliseconds, 10000 milliseconds, 5000 milliseconds, 3000 milliseconds, 2000 milliseconds, 100 milliseconds, 500 milliseconds, 300 milliseconds, 200 milliseconds, 100 milliseconds or shorter; or within the range defined by any two of the aforementioned values. Therefore, the rate of change of the magnetic field amplitude can be greater than approximately 0.05 μT, 0.1 μT, 0.5 μT, 1 μT or greater. The upper limit of the rate of change of the magnetic field amplitude can be determined by the capabilities of the device used to perform the sweep.In some embodiments, when the magnetic field is within the upper and lower limits disclosed above, the spatial deviation of the magnetic field in volume during modulation can be less than about half (or a quarter, or an eighth, or a tenth) of the magnetic field amplitude. For example, when the magnetic field strength is less than 2 μT (or greater than -2 μT), the spatial deviation of the magnetic field in volume during modulation can be less than 1 μT (or less than 0.5 μT, 0.25 μT, or 0.2 μT). As another example, when the magnetic field strength is less than 10 μT (or greater than -10 μT), the spatial deviation of the magnetic field in volume during modulation can be less than 5 μT (or less than 2.5 μT, 1.25 μT, or 1.0 μT). For example, the spatial deviation can be measured by performing at least 10, 30, 50, 100, or 500 spatially random or spatially uniformly distributed measurements of the magnetic field within the volume and calculating the standard deviation of the sampled magnetic field measurements. Such uniformity can be achieved, for example, in a large, uniform magnetic shield by having a large penetrating solenoid that passes through the magnetic shield or by using a large Helmholtz coil with a large uniform region, to generate magnetic field amplitude modulation. In some embodiments, modulation is a sweep of the magnetic field. In some embodiments, magnetic field amplitude modulation includes non-adiabatic jumps, monotonic amplitude variations, or combinations thereof.

[0126] In some embodiments, after the polarization transfer step, the non-hydrogen nuclear spin polarization of the bioassociated imaging agent is greater than 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or greater; less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less; or within the range defined by any two of the foregoing values. In some embodiments, this polarization is achieved for the following solution volumes: greater than about 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 20 ml, 30 ml, 40 ml, 50 ml, 60 ml, 70 ml, 80 ml, 90 ml, 100 ml, 200 ml, 300 ml, 400 ml, 500 ml or greater; or less than about 500 ml, 400 ml, 300 ml, 200 ml, 100 ml, 90 ml, 80 ml, 70 ml, 60 ml, 50 ml, 40 ml, 30 ml, 20 ml, 10 ml, 9 ml, 8 ml, 7 ml, 6 ml, 5 ml, 4 ml, 3 ml, 2 ml, 1 ml or less; or within the range defined by any two of the foregoing values. In various embodiments, after polarization transfer, a portion of the population of the secondary hydride proton spin state has been transferred to the target of the biorelevant imaging agent (e.g., 13C) Nuclear spin polarization. This portion may be greater than 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more; less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less; or within the range defined by any two of the foregoing values.

[0127] In some embodiments, magnetic field modulation includes nonadiabatic hopping of the magnetic field, where hopping is defined as a change in the magnetic field faster than 1 μT, 5 μT, or 10 μT per second. Nonadiabatic hopping can be performed in the magnetic field where energy levels involving proton spin and nonproton spin avoid crossing. Given the J-coupling between nuclear spins in the system, this value can be determined analytically or by plotting the energy levels of the Hamiltonian for different magnetic fields and identifying the LAC. In some embodiments, the duration of the magnetic field amplitude under LAC conditions is less than 2 seconds, 1 second, or 0.5 seconds.

[0128] In some embodiments, modulation of the magnetic field amplitude may involve monotonically changing the magnetic field amplitude (or monotonically changing it over each of a finite number of intervals, such as one to ten increasing intervals and / or one to ten decreasing intervals). In various embodiments, modulation of the magnetic field amplitude involves linearly changing the magnetic field amplitude. The initial magnetic field amplitude, the ending magnetic field amplitude, and the total duration of the sweep can be optimized for the target compound. In some embodiments, the magnetic field amplitude during the sweep is within a lower and upper limit. The lower limit can be greater than about -2 μT, -1 μT, -0.9 μT, -0.8 μT, -0.7 μT, -0.6 μT, -0.5 μT, -0.4 μT, -0.3 μT, -0.2 μT, -0.1 μT or greater; less than about -0.1 μT, -0.2 μT, -0.3 μT, -0.4 μT, -0.5 μT, -0.6 μT, -0.7 μT, -0.8 μT, -0.9 μT, -1 μT, -2 μT or less; or within the range defined by any two of the foregoing values. The upper limit can be greater than about 0.1 μT, 0.2 μT, 0.3 μT, 0.4 μT, 0.5 μT, 0.6 μT, 0.7 μT, 0.8 μT, 0.9 μT, 1 μT, 2 μT or greater; less than about 2 μT, 1 μT, 0.9 μT, 0.8 μT, 0.7 μT, 0.6 μT, 0.5 μT, 0.4 μT, 0.3 μT, 0.2 μT, 0.1 μT or less; or within the range defined by any two of the aforementioned values. In some embodiments, the duration of modulation can be greater than about 100 ms, 200 ms, 300 ms, 500 ms, 1000 ms, 2000 ms, 3000 ms, 5000 ms, 10000 ms or greater; less than about 10000 ms, 5000 ms, 3000 ms, 2000 ms, 1000 ms, 500 ms, 300 ms, 200 ms, 100 ms or less; or within the range defined by any two of the foregoing values. In some embodiments, the rate of amplitude change varies along the amplitude profile. In some embodiments, a constant adiabatic sweep is calculated by selecting a subset of the energy levels of the spin system to avoid crossing. In some embodiments, magnetic amplitude modulation includes a combination of nonadiabatic hopping, monotonic amplitude modulation, and rate-of-change sign switching.

[0129] In some embodiments, when both the secondary hydrogen and the target compound are combined with the polarized catalyst, certain magnetic field amplitudes can support spontaneous spin-level transfer between them. For example, SABRE-SHEATH can use magnetic fields greater than about 100 nT, 200 nT, 300 nT, 400 nT, 500 nT, 600 nT, 700 nT, 800 nT, 900 nT, 1 mT or greater; less than about 1 mT, 900 nT, 800 nT, 700 nT, 600 nT, 500 nT, 400 nT, 300 nT, 200 nT, 100 nT or less; or within the range defined by any two of the foregoing values. As another example, SABRE-SHEATH can use magnetic fields greater than 0.1 mT and less than 100 mT to support such spin-level transfer in 1H polarization. The spin level of secondary hydrogen can be transferred to the polarization on the target compound, or to the spin level on the target compound. In some embodiments using SABRE, the magnetic field value is varied between two or more fixed values ​​to produce an average kinetic that leads to polarization transfer.

[0130] In alternative embodiments, polarization transfer occurs in a magnetic field above 0.1 G and below 200,000 G, by applying a transfer waveform using a continuous RF wave or pulse to transfer the spin level from the bound secondary hydrogen to the nuclear spin polarization in the catalyst-bound target compound. SLIC-SABRE, SABRE-INEPT, or ADAPT sequences can be used, for example, for high-field SABRE transfer.

[0131] In another embodiment, the polarization of the 1H nucleus on the SABRE polarized molecule (either direct polarization or polarization from another nucleus on the same molecule via polarization transfer) is transferred to the target compound via chemical exchange, such as using the SABRE-RELAY method.

[0132] Purification and separation

[0133] In some embodiments, the precursor may be selected such that, following hydrogenation and other potential chemical reactions, one of the products is a biorelevant imaging agent suitable for HP MRI applications. In some embodiments, the biorelevant imaging agent may be generated by further chemical reactions following hydrogenation. Such further chemical reactions may involve, for example, cleaving the side arms of the molecule via hydrolysis. For example, the ester of the biorelevant imaging agent can be polarized using the PHIP-SAH method. Following hydrogenation and polarization transfer, the ester can be cleaved to produce a hyperpolarized biorelevant imaging agent.

[0134] The volume of the solution containing the target compound after cleavage (and the resulting concentration of the target compound) can depend on the volume of the solution used for polarization transfer and the concentration of the precursor in that solution. Exemplary ranges for solution volume and precursor concentration are described herein. As another specific example, at least 1 ml of solution containing at least 10 mM of target compound can be produced. Alternatively, at least 5 ml of solution containing at least 50 mM of target compound can be produced. Alternatively, at least 10 ml of solution containing at least 100 mM of target compound can be produced.

[0135] Consistent with the disclosed embodiments, the properties of the solution containing the hyperpolarized target compound can be altered to induce precipitation of the hyperpolarized target compound after polarization transfer (and, in the PHIP-SAH embodiment, cleavage of the precursor to generate the hyperpolarized target compound).

[0136] Such precipitation allows for the separation of hyperpolarized target compounds (or hyperpolarized precursors) from other substances in solution (e.g., sidearm fragments in the examples using PHIP-SAH, hydrogenation catalysts, hyperpolarized catalysts in the examples using SABRE, etc.). The precipitate can form crystals, amorphous solid particles, polycrystalline materials, etc. Following precipitation, at least a fraction of the solid hyperpolarized target compound (or hyperpolarized precursor) can be separated from the solution and other substances in it. For example, the mixture of precipitate and solution can be filtered to remove particles. The filtered precipitate can be washed with a second solvent. The second solvent can be selected to remove residues of the original solvent and other substances from the solution without completely dissolving the filtered precipitate. In some embodiments, the washing step occurs for less than about 300 seconds, 200 seconds, 100 seconds, 90 seconds, 80 seconds, 70 seconds, 60 seconds, 50 seconds, 30 seconds, 20 seconds, or 10 seconds; more than about 10 seconds, 20 seconds, 30 seconds, 50 seconds, 60 seconds, 70 seconds, 80 seconds, 90 seconds, 100 seconds, 200 seconds, or 300 seconds; or within the range defined by any two of the foregoing values. Precipitation can be carried out using aqueous solutions or solutions containing organic solvents such as acetic acid, acetone, acetonitrile, benzene, 1-butanol, 2-butanol, 2-butanone, tert-butanol, carbon tetrachloride, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, diethylene glycol, diethyl ether, diethylene glycol dimethyl ether, 1,2-dimethoxyethane (dimethyl glycol dimethyl ether, DME), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, and ethanol. Ethyl acetate, ethylene glycol, glycerol, heptane, hexamethylphosphoramide (HMPA), hexamethylphosphotriamide (HMPT), hexane, methanol, methyl tert-butyl ether (MTBE), dichloromethane, N-methyl-2-pyrrolidone (NMP), nitromethane, pentane, petroleum ether (volatile oil), 1-propanol, 2-propanol, pyridine, tetrahydrofuran (THF), toluene, triethylamine, water, heavy water, o-xylene, m-xylene, and p-xylene. In some embodiments, organic solvents are used for the polarization and precipitation steps. For example, secondary hydrogens may be more soluble in a range of organic solvents than in aqueous solutions. Therefore, hydrogenation can be performed more efficiently in such solvents. Thus, in some embodiments using PHIP or PHIP-SAH, secondary hydrogen-induced polarization can occur in a solution formed with an organic solvent. In various embodiments, aqueous solutions are used for hydrogenation and polarization transfer. In some embodiments, this aqueous solution may be mixed with a miscible organic solvent prior to the precipitation of the hyperpolarized target compound.

[0137] In some embodiments, precipitation of the target compound can be induced by altering the pH of the solvent. In organic solvents, certain biorelevant imaging agents (e.g., carboxylic acids, pyridines, etc.) are soluble at concentrations suitable for polarization using PHIP, PHIP-SAH, or SABRE. However, salts of these biorelevant imaging agents can be highly insoluble. For example, such salts can be insoluble at concentrations below about 10 mM, 1 mM, 0.1 mM, 0.01 mM or lower; above about 0.01 mM, 0.1 mM, 1 mM, 10 mM or higher; or within the range defined by any two of the foregoing values. The organic solution may contain concentrations of the biorelevant imaging agent suitable for hyperpolarization using PHIP, PHIP-SAH, or SABRE. After polarization, the pH of the organic solution can be altered to induce precipitation of the salts of the biorelevant imaging agent. In aqueous solutions, salts of certain biorelevant imaging agents (e.g., fumarates, glutamates, etc.) are more soluble than their acidic forms. Therefore, the aqueous solution can contain a concentration of biorelevant imaging agent suitable for hyperpolarization using PHIP, PHIP-SAH, or SABRE. Following polarization, the pH of the aqueous solution can be lowered to induce precipitation of the biorelevant imaging agent in its acidic form.

[0138] Consistent with the disclosed embodiments, pH changes can be induced by adding acidic or basic molecules (such as sodium chloride or sodium hydroxide) to the solution. In some embodiments, pH changes can be induced by mixing the solution with another solution having a substantially different pH. In some embodiments, precipitation due to pH changes occurs within the following timeframes: less than about 100 seconds, 90 seconds, 80 seconds, 70 seconds, 60 seconds, 50 seconds, 40 seconds, 30 seconds, 20 seconds, 10 seconds, 9 seconds, 8 seconds, 7 seconds, 6 seconds, 5 seconds, 4 seconds, 3 seconds, 2 seconds, 1 second or less; or greater than about 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds, 70 seconds, 80 seconds, 90 seconds, 100 seconds or longer; or within the range defined by any two of the foregoing values.

[0139] In some embodiments, precipitation of the target compound can be induced without altering the pH of the solution in which the hyperpolarized target compound varies between salt and acid forms.

[0140] In some embodiments, hydrogenation and polarization transfer can occur in a first solution having a first solvent. The target compound can have high solubility in the first solvent. Precipitation can be induced by mixing the first solution with a second solvent to form a second solution. The second solvent can be selected such that the solubility of the target compound in the second solution is low enough to initiate precipitation.

[0141] In some embodiments, the temperature of the solution is changed, thereby reducing the solubility of the hyperpolarized molecules and inducing precipitation. In most solvents, solubility decreases with decreasing temperature. The temperature change to the desired temperature with lower solubility preferably occurs within the following timeframes: less than about 100 seconds, 50 seconds, 30 seconds, 20 seconds, 10 seconds, 5 seconds, 3 seconds, 2 seconds, 1 second or less; greater than about 1 second, 2 seconds, 3 seconds, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 50 seconds, 100 seconds or longer; or within the range defined by any two of the foregoing values. For example, the maximum mole fraction of acetic acid in n-heptane is 0.935 at 14.8 °C, only 0.02 at -29.2 °C, and even lower at lower temperatures. The selected precipitation temperature can be chosen to be above the solvent's freezing point.

[0142] In some embodiments, the surface area of ​​the solution can be increased to induce nucleation of the precipitate. This can be achieved, for example, by jetting the solution through a nozzle to generate very small droplets with a high surface area. In some embodiments, microcrystalline seeds (which may be a target compound or another biocompatible compound) can be added to the solution to induce precipitation.

[0143] In some embodiments, the pressure of the solution is changed, thereby reducing the solubility of the hyperpolarized compound and inducing precipitation.

[0144] In some embodiments, the concentration of the hyperpolarized target compound is increased above its solubility limit, thereby inducing precipitation without reducing the compound's solubility level in the solvent. This can be achieved, for example, by adding nonpolarized molecules of the target compound or by evaporating a volume of solvent, thereby increasing the concentration of the target compound above its solubility limit.

[0145] In some embodiments, the polarization parameters of PHIP, PHIP-SAH, or SABRE can be optimized for high concentrations, preferably above the solubility limit of the target compound in its acid or salt form, even at the cost of lower polarization. This can be achieved, for example in PHIP or PHIP-SAH, by starting with a high concentration of the precursor for hydrogenation and selecting a long hydrogenation time, which can lead to a reduction in polarization due to relaxation. In SABRE, this can be achieved by increasing the concentration of the target compound, at the cost of lower polarization transfer efficiency from secondary hydrogens.

[0146] In some embodiments, precipitation can be accelerated by adding mechanical energy or by improving the mixing of the mixture over a certain period of time. This can be done, for example, by applying ultrasound to the mixture via an ultrasonic cleaner, or by mechanical or magnetic mixing of the sample. In some embodiments, the additional mixing or introduction of mechanical energy is carried out for a period of time greater than about 0.1 seconds, 1 second, 5 seconds, 10 seconds or longer; less than about 10 seconds, 5 seconds, 1 second, 0.1 seconds or less; or within the range defined by any two of the foregoing values.

[0147] In some embodiments, precipitation can be induced by a chemical reaction involving a hyperpolarized target compound. The hyperpolarized target compound may react with another compound or in response to an external stimulus, such as electromagnetic radiation (e.g., UV irradiation). The solubility of the product of this reaction can be reduced compared to the hyperpolarized target compound, thereby inducing precipitation. For example, the external stimulus can alter the structure of the hyperpolarized target compound, thereby reducing its solubility. After the precipitate is redissolved, further reactions can be carried out to produce the desired end product (e.g., a bio-related imaging agent, NMR material, etc.).

[0148] In some embodiments, hydrolysis of the precursor can induce precipitation. In some embodiments, such as using PHIP-SAH, the solvent can be selected such that the precursor is more soluble than the target compound. The concentration of the precursor in the solution can be selected such that the target compound precipitates from the solution after cleavage of the side arm and generation of the target compound. In some such embodiments, cleavage can be initiated by changing the pH of the solution. For example, cleavage can be initiated by adding a base (e.g., sodium hydroxide or another suitable base). In some embodiments, the solution can be formed with an organic solvent, and cleavage can be carried out under alkaline conditions. After cleavage, the less soluble target compound undergoes rapid precipitation while maintaining its polarization. The same solution can be used for hydrogenation, polarization transfer, and precipitation, or another solvent can be mixed into the solution used for hydrogenation and polarization transfer.

[0149] In some embodiments using PHIP-SAH, precursor precipitation can occur prior to cleavage. Such embodiments may be suitable when the precursor is more stable than the target compound. Precipitation can be induced by altering the pH of the solution to reduce the solubility of the precursor, or by mixing in a solution or compound with reduced precursor solubility. In such embodiments, precursor cleavage can occur after the precursor has been redissolved in a solvent. The precursor can be filtered and washed as described herein to remove other substances present in the original solution, such as hydrogenation catalysts. The precursor can then be reacted (e.g., by cleaving the side arms) to form the target compound. The target compound can be separated from other reaction products by liquid-liquid extraction or by an additional precipitation step consistent with the precipitation methods described herein. In some embodiments using PHIP-SAH, precipitation can occur after the target compound has been generated from the precursor. Such precipitation can be performed according to the methods described herein.

[0150] In some embodiments, a spin-to-polarization transition occurs before the compound is solidified and precipitated. In other embodiments, this transition occurs after the crystal is redissolved with the target compound.

[0151] In some embodiments, a series of steps including precipitation, washing, and redissolution are performed. This may facilitate further purification of the target compound, increase the relaxation time of the precipitate, or further separation of polarization and cleavage steps. For example, the first precipitate may be used to wash out the catalyst, while the second precipitate is in a crystalline form with a longer relaxation time and can be used for transport. In another embodiment, the first precipitate is an ester of the target compound after hydrogenation and polarization transfer, and the second precipitation is performed after cleavage.

[0152] Consistent with the disclosed embodiments, the precipitation (and optionally washing) step can separate the hyperpolarized target compound (or hyperpolarized precursor) from other substances in the original solution (e.g., catalyst, original solvent, reaction products, etc.). For example, after the target compound precipitates, most of the hydrogenation catalyst present in the original solution can remain in the original solution. In some embodiments, the precipitate (optionally after washing) can retain less than about 1%, 0.1%, 0.01%, 0.001%, or less of the hydrogenation catalyst; or retain more than about 0.001%, 0.01%, 0.1%, 1%, or more of the hydrogenation catalyst. Similarly, in embodiments using PHIP-SAH and cleaving precursor molecules prior to precipitation, the precipitation may retain less than about 1%, 0.1%, 0.01%, 0.001% or less of cleavage byproducts (e.g., cleaved side arms or other residues); retain more than about 0.001%, 0.01%, 0.1%, 1% or more of cleavage byproducts; or keep the amount of cleavage byproducts within the range defined by any two of the foregoing values.

[0153] In some embodiments, the amount of hyperpolarized particles in the precipitate is accumulated over several iterations of hydrogenation, polarization transfer, and precipitation of another target compound.

[0154] Hyperpolarized solid particles, particularly micron-sized hyperpolarized solid particles, can be a valuable resource for several applications. Some applications involve using microparticles as NMR / MRI tracers, for example, when using microparticles that are insoluble in aqueous solutions. In some embodiments, solid hyperpolarized compounds obtained by precipitation using PHIP, PHIP-SAH, or SABRE hyperpolarizing solutions are dissolved in a solvent and used as hyperpolarizing agents in hyperpolarized NMR or MRI.

[0155] In some embodiments, after precipitation and separation from the original solvent (and potential transport of the hyperpolarized precipitate), the precipitate can be redissolved in a solvent (e.g., for use as a reagent in hyperpolarized MRI). Preferably, the solvent is a biocompatible solvent, preferably an aqueous solution. In some embodiments, redissolution occurs within the following timeframes: less than about 60 seconds, 30 seconds, 20 seconds, 10 seconds, or 5 seconds; greater than about 5 seconds, 10 seconds, 20 seconds, 30 seconds, or 60 seconds or longer; or within the range defined by any two of the foregoing values.

[0156] In some embodiments, after redissolution, the target compound may be present at a higher concentration than that used during PHIP, PHIP-SAH, or SABRE polarization. In some embodiments, the concentration of the hyperpolarized target compound after redissolution is greater than or equal to about 100 mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, 500 mM, or less than or equal to about 500 mM, 450 mM, 400 mM, 350 mM, 300 mM, 250 mM, 200 mM, 150 mM, 100 mM; or within the range defined by any two of the foregoing values. Therefore, the concentration of the precursor or target compound during polarization can be independent of the concentration of the molecules in the injection solution. The concentration of the precursor or target compound during polarization can be selected for effective polarization transfer. In some embodiments, this polarization concentration may be less than the concentration of the hyperpolarized target compound after redissolution. For example, the polarization concentration can be less than about 300 mM, 200 mM, 150 mM, 140 mM, 130 mM, 120 mM, 110 mM, 100 mM, 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 20 mM, 10 mM or less; or greater than about 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 200 mM, 300 mM or more; or within the range defined by any two of the foregoing values. In some embodiments, the precipitate sample may exhibit polarization greater than about 30%, 20%, 10%, 5%, 1% or less; or less than about 1%, 5%, 10%, 20%, 30% or more. After particle redissolution, the concentrations of the catalyst, precursor, or cleavage byproduct may each be less than 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or Smaller; greater than 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, 9 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1 μM or larger; or within the range defined by any two of the foregoing values.In some embodiments, the purity of the redissolved hyperpolarized target compound is greater than 90%, 92%, 95%, 98%, 99%, or higher; less than 99%, 98%, 95%, 92%, 90%, or lower; or within the range defined by any two of the foregoing values. In various embodiments, at least a portion of the hyperpolarized compound can be separated from the cleaved side arms or other reaction byproducts (if present).

[0157] Figure 4 An exemplary schematic diagram of a polarizer 400 for obtaining a high-concentration biocompatible solution with a hyperpolarized target compound is depicted. The polarizer 400 can be used with PHIP, PHIP-SAH, or SABRE polarization methods. In a secondary hydrogenation chamber 401, secondary hydrogen can be dissolved in a solution containing a catalyst and the target compound. Chamber 401 can be of various designs known in the art to dissolve large amounts of secondary hydrogen in solution and achieve high efficiency in hydrogenation or polarization transfer. In some embodiments, chamber 401 may include an inlet for introducing secondary hydrogen into the solution at high pressure. In various embodiments, chamber 401 may be or include a flow chamber in which a membrane separates the solution and the flowing secondary hydrogen gas, allowing the secondary hydrogen to dissolve in the solution with a high surface area. In another embodiment, chamber 401 may be a secondary hydrogen chamber in which the solution is sprayed into the chamber in the form of small droplets, thereby establishing a large surface area for dissolving secondary hydrogen.

[0158] The polarization transferring the spin order of a secondary hydrogen molecule to a target compound can be performed in polarization transfer chamber 402. For example, for PHIP or PHIP-SAH polarization, polarization can be transferred by passing through a specific low magnetic field, typically below 1 μT, during or after hydrogen dissolution. In another embodiment, the magnetic field sweep encompasses at least some range between -10 μT and 10 μT. In yet another embodiment, a magnetic field of 0.1 G or higher can be used, and polarization transfer can be induced by a sequence of RF irradiations. In SABRE polarization, in certain embodiments, polarization transfer occurs by dissolving hydrogen in a specific magnetic field. This magnetic field can be below the Earth's magnetic field and thus require magnetic shielding as used in SABRE-SHEATH, or it can be above the Earth's magnetic field, as in 1H polarization via SABRE. In another embodiment, a magnetic field above 0.1 G is used, and polarization transfer is induced by a sequence of RF irradiations.

[0159] Precipitation chamber 403 can be used to induce precipitation of a hyperpolarized target compound. In some embodiments, chamber 403 may include an inlet (e.g., a reagent port, etc.) for introducing powder or solution (e.g., a precipitant) to mix with a solution containing the hyperpolarized target compound and induce precipitation. In some embodiments, chamber 403 may include a stimulation port for introducing electromagnetic radiation (e.g., ultraviolet radiation, etc.) into chamber 403. As described herein, electromagnetic radiation can cause a decrease in solubility in the structure of the hyperpolarized target compound (e.g., thereby inducing precipitation of the hyperpolarized target compound). In some embodiments, the added powder or solution may contain a base or acid, such as sodium hydroxide, potassium hydroxide, hydrogen chloride, or sulfuric acid. In some embodiments, the added powder or solution may induce hydrolysis of the hyperpolarized compound.

[0160] In some embodiments, chamber 403 may include a separation component for separating precipitated compounds from the solution. In some embodiments, this component may be a filter that allows solvent to pass through but not microparticles. An example filter is a commercially available sterile filter. In another embodiment, the separation component may include a centrifuge configured to separate the precipitate from the solution by centrifugation (or to separate different precipitates by particle size). In another embodiment, sufficient time is given to allow the precipitated crystals to settle to the bottom of the separation component, preferably in the designed orifices, which allows the solution to be washed or diluted with little effect on the precipitated particles. In another embodiment, the separation component may include a heating element to heat and evaporate the solution and preserve the precipitated particles. In another embodiment, the separation component may include temperature and pressure controllers to allow the sample to be separated by a freeze-drying method, comprising a mixture of a frozen sample and sublimated particles to remove the precipitate.

[0161] In some embodiments, chamber 403 may include an inlet for introducing a solution for the washing step, wherein the solvent containing the catalyst is washed away or significantly diluted with a washing fluid. In some embodiments, the washing fluid is biocompatible. For example, if the separation assembly includes a filter, the washing fluid may flow through the filter to wash precipitated particles from the original solvent.

[0162] A magnetic field generated by a permanent magnet or electromagnet 404 can be applied to at least a portion of the settling chamber. In one embodiment, the magnetic field is applied to most or all of the settling chamber. The magnetic field can be configured such that some of the precipitated particles are subjected to magnetic fields greater than about 1 mT, 10 mT, 100 mT, 1 T, 2 T or greater; or less than 2 T, 1 T, 100 mT, 10 mT, 1 mT or less.

[0163] In some embodiments, large volumes of hyperpolarized particles of precipitate can be accumulated through repeated iterations of secondary hydrogen dissolution, hyperpolarized target compound, and precipitation. This can be carried out in a continuous flow, discrete batches, or a mixture of continuous flow and discrete batches. In some embodiments, some steps are performed simultaneously on several batches, while other steps are performed sequentially on each batch. This may occur, for example, when one step can be performed on a larger volume than other steps. For example, in some embodiments, secondary hydrogen dissolution can be performed on solution volumes greater than about 5 ml, 20 ml, 50 ml, 100 ml, or larger (or less than about 100 ml, 50 ml, 20 ml, 5 ml, or smaller), while polarization transfer can be performed on a smaller volume. In some embodiments, secondary hydrogen dissolution will be performed on a large volume of solution, while polarization transfer will be performed sequentially on smaller batches. In this example, precipitation can be performed sequentially on each batch after polarization transfer, or alternatively on larger batches after the accumulation of a larger volume of hyperpolarized target compound following polarization transfer.

[0164] The particles are then dissolved in a dissolution or extraction chamber 405, whereby the particles are redissolved and extracted for detection in hyperpolarized NMR or MRI. In some embodiments, redissolution can be performed in a biocompatible solvent. In a preferred embodiment, the solvent is an aqueous solution. In a preferred embodiment, the dissolution chamber includes an inlet for introducing the solvent. In a preferred embodiment, the dissolution chamber includes an outlet. In another embodiment, the dissolved particles are injected directly into the patient from the dissolution chamber in an HP MRI scanner. In a preferred embodiment, a magnetic field generated by a permanent magnet or electromagnet is applied to the dissolution chamber. The magnetic field in the region of the precipitated particles before dissolution can be greater than about 1 mT, 10 mT, 100 mT, 1 T, 2 T or greater; less than 2 T, 1 T, 100 mT, 10 mT, 1 mT or less; or within the range defined by any two of the foregoing values.

[0165] In some embodiments, chambers 203 and 205 may be the same chamber. This chamber may optionally be transported to different locations between precipitation and dissolution. In some embodiments, chambers 201 and 203 may be the same chamber.

[0166] transportation

[0167] Consistent with the disclosed embodiments, polarization transfer and use of the target compound can occur at different locations. In various embodiments, the precursor (in the solution used for polarization transfer or as a precipitate) can be transported to another location after precipitation. In various embodiments, the target compound (in the solution used for polarization transfer, as a precipitate or redissolved) can be transported to another location. The disclosed embodiments are not necessarily limited to any particular transport distance or duration. Rather, the maximum distance or duration can be determined based on the target compound, its initial degree or polarization, the desired final degree of polarization, and the transport conditions. In some embodiments, the precipitate can be transported at least one meter in a suitable transport device.

[0168] Consistent with the disclosed embodiments, the transport device can be configured to transport samples of precursors or target compounds. The transport device can be arranged and configured for the simultaneous transport of one or more samples. The transport device may include a transport chamber configured to receive one or more samples. The transport device can be configured to maintain the transport chamber within a predetermined temperature range and a predetermined magnetic field strength. The transport device can be configured to maintain one or more samples in a magnetic field greater than about 10 G, 100 G, 1000 G, or greater; or less than 1000 G, 100 G, 10 G, or less.

[0169] Permanent magnets or electromagnets included in the transport device can provide a magnetic field. Furthermore, in some embodiments, the permanent magnets or electromagnets can be shielded to reduce the magnetic field strength outside the transport device. The transport device may also include a cooling system. The cooling system can be configured to maintain the sample at a predetermined temperature or within a predetermined temperature range during transport. For example, the cooling system can be configured to maintain the sample at temperatures below 270K, below 80K, or below 4K. In some embodiments, the transport device can be configured to maintain the sample at approximately the temperature of liquid nitrogen. The transport device may include a thermal insulation layer between the cooling system and the exterior of the transport device to minimize heat exchange with the external environment. In some embodiments, the cooling system can be configured to use a cold airflow to maintain the sample temperature. In various embodiments, the cooling system can be configured to use a liquid coolant to maintain the sample temperature. In various embodiments, the transport device may include a Dewar to provide cooling for the sample. To distribute the hyperpolarized sample over a large distance, the container is preferably transported by standard means of transport, such as airplanes, trains, trucks, cars, and ships.

[0170] In some embodiments, the hyperpolarized precipitated particles are transported in a transport device. In some embodiments, the relaxation time of the hyperpolarized precipitated particles in the transport device is longer than about 1 minute, 10 minutes, 30 minutes, 1 hour, 3 hours, 10 hours or longer; or shorter than about 10 hours, 3 hours, 1 hour, 30 minutes, 10 minutes, 1 minute or less.

[0171] Exemplary System

[0172] Figure 5A , 5B Figures 5 and 5C each depict exemplary schematic diagrams of systems comprising a polarizer and a separation system, wherein the polarizer is used to obtain a high-concentration biocompatible solution containing a hyperpolarized target compound. Such systems can be used with PHIP, PHIP-SAH, or SABRE polarization methods. Figure 5A An exemplary polarizer 500, consistent with the disclosed embodiments, is depicted. In PHIP or PHIP-SAH embodiments, polarizer 500 may include a hydrogenation device configured to produce a solution of a secondary hydrogenated precursor of the target compound (e.g., a secondary hydrogenated precursor solution). The hydrogenation device can produce the secondary hydrogenated precursor solution by mixing a solvent, secondary hydrogen gas, and a precursor of the target compound. In some embodiments, the hydrogenation device may mix a solution containing a precursor dissolved in a solvent (e.g., a precursor solution). In some embodiments, the precursor may contain unsaturated chemical bonds. The secondary hydrogen gas can react with the precursor at the unsaturated chemical bonds to form the secondary hydrogenated precursor. In some embodiments, the precursor may be a pyruvate precursor containing at least one unsaturated bond, a fumarate precursor containing at least one unsaturated bond, or a succinate precursor containing at least one unsaturated bond. In SABRE embodiments, the hydrogenation device may combine a solution containing the target compound and a polarization catalyst with secondary hydrogen. The hydrogenation catalyst can bring the secondary hydrogen closer to the target compound to achieve polarization transfer.

[0173] Consistent with the disclosed embodiments, the hydrogenation apparatus may include a secondary hydrogenation chamber 501. Chamber 501 may be designed and configured to contain a combination of solvent (or precursor solution) and secondary hydrogen. Chamber 501 may be designed and configured to achieve high hydrogenation efficiency. The secondary hydrogen may combine with the solvent (or precursor solution) for a time interval (or the dissolution of the secondary hydrogen may occur within a shorter time interval). The time interval may be less than about 90 seconds, 60 seconds, 30 seconds, 20 seconds, 10 seconds, 5 seconds or less; greater than about 5 seconds, 10 seconds, 20 seconds, 30 seconds, 60 seconds, 90 seconds or longer; or within the range defined by any two of the foregoing values. In some embodiments, the precursors are hydrogenated to: greater than about 30 mM, 50 mM, 100 mM, 250 mM, 400 mM, 600 mM, 1000 mM or more; less than about 1000 mM, 600 mM, 400 mM, 250 mM, 100 mM, 50 mM, 30 mM or less; or within the range defined by any two of the foregoing values.

[0174] In some embodiments, chamber 501 may include a bubbler configured to introduce secondary hydrogen gas into a solvent (or precursor solution). For example, chamber 501 may include an inlet for introducing pressurized secondary hydrogen into the solvent (or precursor solution). In some embodiments, the solvent (or precursor solution) into the hydrogenation chamber is introduced with secondary hydrogen at pressures of at least about 10 bar, 15 bar, 20 bar, 25 bar, 30 bar, 35 bar, 40 bar, 45 bar, 50 bar or greater; at most about 50 bar, 45 bar, 40 bar, 35 bar, 30 bar, 25 bar, 20 bar, 15 bar, 10 bar or less; or within a range defined by any two of the foregoing values. In some such embodiments, the high-pressure dissolution of secondary hydrogen in the solvent (or precursor solution) occurs in a metal chamber capable of withstanding the pressure required to introduce secondary hydrogen. In other embodiments, the chamber is made of a plastic material. In some embodiments, the bubbler includes a nozzle head that introduces secondary hydrogen into the solvent (or precursor solution) within microbubbles to obtain a larger surface area.

[0175] In various embodiments, chamber 501 may be a flow chamber. In such embodiments, the membrane may separate the solvent (or precursor solution) and the flowing secondary hydrogen gas. The membrane may be arranged within the flow chamber to have a high surface area so that the secondary hydrogen can dissolve in the solvent (or precursor solution).

[0176] In various embodiments, chamber 501 may comprise a chamber filled with secondary hydrogen gas. An atomizer in chamber 501 may be configured to spray solvent (or precursor solution) into the chamber in the form of small droplets, thereby creating a large surface area for dissolving the secondary hydrogen.

[0177] In some embodiments, a heating coil 505 may be disposed around or inside the chamber 501. Such a coil may be energized to control the temperature of the solution within the chamber 501.

[0178] Consistent with the disclosed embodiments, the polarization device may include a polarization chamber 502. The polarization chamber 502 may be configured to receive a secondary hydrogenation precursor solution from the hydrogenation device. The polarization chamber 502 may include a polarization region having a defined volume. The volume can be at least about 10 mL, 20 mL, 30 mL, 40 mL, 50 mL, 60 mL, 70 mL, 80 mL, 90 mL, 100 mL, 200 mL, 300 mL, 400 mL, 500 mL, 600 mL, 700 mL, 800 mL, 900 mL, 1000 mL or more; 1000 mL, 900 mL, 800 mL, 700 mL, 600 mL, 500 mL, 400 mL, 300 mL, 200 mL, 100 mL, 90 mL, 80 mL, 70 mL, 60 mL, 50 mL, 40 mL, 30 mL, 20 mL, 10 mL or less; or within the range defined by any two of the foregoing values.

[0179] Polarizer 500 may include a polarization device configured to generate a solution of a polarized secondary hydrogenated precursor of the target compound (e.g., a polarized secondary hydrogenated precursor solution). Consistent with the disclosed embodiments, the polarization device may include a magnetic field generator 507 capable of setting the magnetic field amplitude in polarization chamber 502 (or polarization region) to a specific value (or setting the magnetic field to follow a specific time-dependent amplitude trajectory).

[0180] Consistent with the disclosed embodiments, the magnetic field generator 507 can modulate a magnetic field within a specified range between -10 μT and 10 μT within the polarization chamber 502 (or polarization region). In some embodiments, the magnetic field generator 507 can modulate the magnetic field within a specified range. In some embodiments, when the amplitude of the magnetic field during modulation is less than 10 μT, the spatial deviation of the magnetic field during modulation is less than half (or a quarter, or an eighth, or a tenth) of the amplitude of the magnetic field. In some embodiments, such uniformity can be achieved (e.g., in a large uniform magnetic shield) by having a large penetrating solenoid through the magnetic shield or by using a large Helmholtz coil with a large uniform region to generate magnetic field amplitude modulation.

[0181] Modulation can occur over a period of time. In some embodiments, the duration can be between about 100 milliseconds and 30,000 milliseconds (e.g., as described herein). In some embodiments, modulation can be a sweep of a magnetic field. In some embodiments, the magnetic field coil can be controlled by an external waveform generator. The external waveform generator can be configured to generate a varying magnetic field within the magnetic shield to effectively transfer polarization. In some embodiments, such as in SABRE polarization, the magnetic field in polarization chamber 502 can be maintained at less than about 1 μT, 2 μT, 3 μT, 4 μT, 5 μT, 6 μT, 7 μT, 8 μT, 9 μT, 10 μT, 20 μT, 30 μT, 40 μT, 50 μT, 60 μT, 70 μT, 80 μT, 90 μT, 100 μT, 200 μT, 300 μT, 400 μT, 500 μT, 600 μT, 700 μT, 800 μT, 900 μT, 1000 μT or greater. A constant value or range; a constant value or range greater than approximately 1000 μT, 900 μT, 800 μT, 700 μT, 600 μT, 500 μT, 400 μT, 300 μT, 200 μT, 100 μT, 90 μT, 80 μT, 70 μT, 60 μT, 50 μT, 40 μT, 30 μT, 20 μT, 10 μT, 9 μT, 8 μT, 7 μT, 6 μT, 5 μT, 4 μT, 3 μT, 2 μT, 1 μT or less; or within the range defined by any two of the aforementioned values. The magnetic field in polarization chamber 302 can be maintained at a constant value or range of the following: at least about 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds or longer; at most about 60 seconds, 50 seconds, 40 seconds, 30 seconds, 20 seconds, 10 seconds, 9 seconds, 8 seconds, 7 seconds, 6 seconds, 5 seconds, 4 seconds, 3 seconds, 2 seconds, 1 second or shorter; or within a range defined by any two of the foregoing values.

[0182] In some embodiments, magnetic field modulation can be performed by allowing the solution to flow through a region inside a magnetic shield 503 having a constant magnetic field distribution.

[0183] In some embodiments, a single solenoid can be used to control the magnetic field gradient at the entrance and exit of the magnetic shield 503, as well as to modulate the magnetic field inside the shield.

[0184] Consistent with the disclosed embodiments, the polarization device may include a magnetic shield 503. In some embodiments, the magnetic shield 503 may be constructed of μ metal or another suitable shielding material. A magnetic field generator 507 may be disposed within the magnetic shield 503. The polarization region of the polarization chamber 502 may be disposed within the magnetic shield 503. The magnetic shield 503 may enable the application of a magnetic field with an amplitude less than that of the Earth's magnetic field to the solution in the polarization transfer chamber 502. In some embodiments, the magnetic field generator 507 may enable the setting of the magnetic field in the polarization transfer chamber 502 to a specific value (or the setting of the magnetic field to follow a specific time-dependent amplitude trajectory). In some embodiments, the secondary hydrogenation chamber 501 may be at least partially located outside the magnetic shield 503, such as... Figure 5A As shown. Alternatively, the secondary hydrogenation chamber 501 can be within the magnetic shield 503 (e.g., a single reservoir can combine the functions of the secondary hydrogenation chamber 401 and the polarization transfer chamber 402).

[0185] Polarizer 500 may include an RF waveform generator ( Figure 5A (Not shown in the image). The radio frequency waveform generator can be electrically coupled to the magnetic field coil 407. The radio frequency waveform generator can be configured to apply a radio frequency waveform to one or more RF coils, thereby generating an electromagnetic field within the polarization device. The radio frequency waveform generator can be configured to generate varying magnetic field amplitudes within the magnetic shield to effectively transfer polarization.

[0186] In some embodiments, polarizer 500 may be used in conjunction with a purification system configured to separate purified fractions from the polarized solution. In some embodiments, the purification system may include separation system 506. After polarization, a solution containing a polarized precursor (in PHIP in PHIP-SAH applications) or a polarized target compound (in SABRE applications) may be delivered to separation system 506. Separation system 506 may be configured to receive a solution containing a polarized precursor (in PHIP or PHIP-SAH applications) or a polarized target compound (in SABRE applications). In some embodiments, separation system 506 may include connections (e.g., fluid manifolds or other suitable connections) for automatically or manually transferring fluid from polarizer 500. Separation system 506 may be or include a precipitation chamber, as detailed in the “Purification and Separation” section. In some embodiments, the purification system may be configured to receive a cleavage solution. The cleavage solution may cleave side arms from a hyperpolarized secondary hydrogenated precursor, thereby producing a hyperpolarized target compound. As described herein, the cleavage solution can induce a hydrolysis reaction that separates the target compound from the remainder of the precursor molecule. In some embodiments, the cleavage solution can be configured to alter the pH of the solution containing the hyperpolarized secondary hydrogenated precursor. In some embodiments, the redissolution chamber detailed in the "Purification and Separation" section can be a chamber in separation system 506. Thus, after extraction and purification of the hyperpolarized target compound, the hyperpolarized target compound can be dissolved in a biocompatible solvent, preferably an aqueous solvent. In various embodiments, liquid-liquid extraction between an organic phase and an aqueous phase can be performed via separation system 506. Such liquid-liquid extraction can be used to cleave the secondary hydrogenated precursor from the side arm to produce the target compound, and to separate the target compound from the catalyst used for hydrogenation or polarization transfer, cleavage byproducts, or organic solvents. In some embodiments, a fluorinated phase can be used in addition to / as a substitute for the organic phase, and can be combined with the aqueous phase to improve separation. In some other embodiments, the purification step can include catalyst removal. Such catalyst removal can include the addition of a binding material that preferentially binds to the catalyst, wherein the binding material is subsequently separated by filtration, centrifugation, or other mechanical means. In some embodiments, hyperpolarized molecules can be cleaved within separation system 506 to produce target compounds. In some embodiments, the pH level and temperature of the sample can be monitored and controlled within separation system 506 to meet conditions for injection into a patient. Alternatively, a quality control system (similar to quality control system 613) can be used to monitor the characteristics of the sample. The sample can be injected into an animal or human patient for hyperpolarized MRI scanning in an MRI scanner (e.g., as in MRI system 612).

[0187] The disclosed embodiments are not limited to those including magnetic shield 503. In some embodiments (e.g., in which appropriate polarization transfer can occur in an ambient magnetic field), polarizer 500 may omit magnetic shield 503.

[0188] Figure 5B Polarizer 510 is depicted, consistent with the disclosed embodiments. Polarizer 510 may include a hydrogenation device, a polarization device, a radio frequency waveform generator, and a purification system, and is similar in design and function to the embodiments described above. Figure 5A Those described.

[0189] Consistent with the disclosed embodiments, polarizer 510 may include a hydrogenation device similar to the hydrogenation device of polarizer 500. In some embodiments, the hydrogenation device of polarizer 510 may include a secondary hydrogenation chamber 511 similar to secondary hydrogenation chamber 501. In some embodiments, the hydrogenation device of polarizer 510 may optionally include a heater coil 515 similar to heater coil 505.

[0190] Consistent with the disclosed embodiments, polarizer 510 may include a polarization device similar to the polarization device of polarizer 510. In some embodiments, the polarization device of polarizer 510 may include a polarization chamber 512 similar to polarization chamber 502. Polarization chamber 512 may have a volume, configuration, etc. similar to those described with respect to polarization chamber 502.

[0191] According to the disclosed embodiments, the polarization device of polarizer 510 may include a magnetic field generator 517 similar to magnetic field generator 507. Magnetic field generator 517 can modulate a magnetic field within a specified range between 0 mT and 500 mT within polarization chamber 512 (or its polarization region). In some embodiments, magnetic field generator 517 can provide a constant magnetic field. In some embodiments, magnetic field generator 517 can modulate the magnetic field.

[0192] In various embodiments, the magnetic field generator 517 may comprise an electromagnet or a permanent magnet capable of generating magnetic fields greater than 0.1 mT, 0.2 mT, 0.3 mT, 0.4 mT, 0.5 mT, 0.6 mT, 0.7 mT, 0.8 mT, 0.9 mT, 1.0 mT, 2.0 mT, 3.0 mT, 4.0 mT, 5.0 mT, 6.0 mT, 7.0 mT, 8.0 mT, 9.0 mT, 10 mT, 20 mT, 30 mT, 40 mT, 50 mT, 60 mT, 70 mT, and 80 mT. T, 90mT, 100mT, 200mT, 300mT, 500mT; or less than approximately 500mT, 300mT, 200mT, 100mT, 90mT, 80mT, 70mT, 60mT, 50mT, 40mT, 30mT, 20mT, 10mT, 9mT, 8mT, 7mT, 6mT, 5mT, 4mT, 3mT, 2mT, 1mT, 0.9mT, 0.8mT, 0.7mT, 0.6mT, 0.5mT, 0.4mT, 0.3mT, 0.2mT, 0.1mT. A magnetic field can be applied to the sample in polarization chamber 512.

[0193] In some embodiments, the polarization device of polarizer 510 may include a magnetic shield 513 similar to magnetic shield 503. Similar to magnetic shield 503, magnetic shield 513 may be constructed of μ metal or another suitable shielding material. Magnetic field generator 517 may be disposed within magnetic shield 513. The polarization region of polarization chamber 512 may be disposed within magnetic shield 513. Magnetic shield 513 enables the application of a magnetic field with an amplitude less than that of the Earth's magnetic field to the solution in polarization transfer chamber 512.

[0194] In some embodiments, RF coil 514 can be configured to generate a radio frequency waveform on a sample in a chamber for polarization transfer. As used herein, the radio frequency waveform additionally includes an audio waveform. Therefore, the radio frequency waveform can be from 20 Hz to 200 kHz, or from 1 Hz to 1 MHz. In various embodiments, the waveform is configured as a polarization transfer waveform associated with the transfer of polarization on the sample. The polarization transfer waveform can be selected based on the type of compound, the magnetic field, and whether the compound is polarized by the PHIP, PHIP-SAH, or SABRE methods described herein. In various embodiments ( Figure 5B In (not shown), RF coil 514 may be the same coil used in magnetic field generator 517 for generating a static magnetic field, or may contain the same coil. In various embodiments, magnetic field generator 517 may be a solenoid, and RF coil 514 may be arranged as a saddle-shaped coil surrounding the solenoid. Figure 5B(Not shown in the image). In various embodiments, the RF coil 514 can generate an oscillating electromagnetic field, wherein the magnetic field has a component perpendicular to the static magnetic field. In various embodiments, the RF coil 514 can be configured, for example, to use two sets of perpendicular coils to generate a circularly polarized magnetic field. In some embodiments, during the application of a polarization waveform by the RF coil 514, the magnetic shield 513 can be configured to maintain the magnetic field strength in the polarization chamber at at least about 10 mT, 20 mT, 40 mT, 80 mT, 160 mT, 200 mT, 250 mT, 500 mT, 1000 mT or greater; 1000 mT, 500 mT, 250 mT, 200 mT, 160 mT, 80 mT, 40 mT, 20 mT, 10 mT or less; or within a range defined by any two of the foregoing values.

[0195] Polarizer 510 may include a radio frequency (RF) waveform generator similar to an RF waveform generator. The RF waveform generator may be configured to apply one or more RF waveforms over a predetermined time period (e.g., between 0.5 seconds and 30 seconds, or another suitable time period). The RF waveforms may include waveforms having a substantially constant frequency during the time period, waveforms having a substantially linear (or substantially monotonic) frequency variation during the time period, waveforms having a substantially constant amplitude during the time period, and waveforms having a substantially linear (or substantially monotonic) amplitude variation during the time period. One or more channels of the RF waveform generator may be electrically coupled to magnetic field generator 517, and RF waveforms may be applied to magnetic field generator 517. One or more channels of the RF waveform generator may be electrically coupled to RF coil 514. In various embodiments, one or more channels connected to RF coil 514 are configured to generate RF waveforms during polarization transition.

[0196] The radio frequency electromagnetic field generated by RF coil 514 can be used to perform polarization transfer to the target nucleus spin in polarization chamber 512 with sample volumes of at least about 10 mL, 20 mL, 30 mL, 40 mL, 50 mL, 60 mL, 70 mL, 80 mL, 90 mL, 100 mL, 200 mL, 300 mL, 400 mL, 500 mL, 600 mL, 700 mL, 800 mL, 900 mL, 1000 mL or more; 1000 mL, 900 mL, 800 mL, 700 mL, 600 mL, 500 mL, 400 mL, 300 mL, 200 mL, 100 mL, 90 mL, 80 mL, 70 mL, 60 mL, 50 mL, 40 mL, 30 mL, 20 mL, 10 mL or less; or within the range defined by any two of the foregoing values.

[0197] In some embodiments where the secondary hydrogenation chamber 511 is the polarization chamber 512, the RF coil 514 can generate continuous wave irradiation or pulses during hydrogenation to react secondary hydrogenated protons with deuterium or... 13 C-spin decoupling.

[0198] In some embodiments, the radio frequency waveform may include pulses, frequency sweeps, or amplitude sweeps for polarization transfer as described in the "Polarization Transfer" section. In some embodiments, such as in SABRE polarization, the radio frequency waveform in polarization chamber 402 may be maintained at less than about 1 μT, 2 μT, 3 μT, 4 μT, 5 μT, 6 μT, 7 μT, 8 μT, 9 μT, 10 μT, 20 μT, 30 μT, 40 μT, 50 μT, 60 μT, 70 μT, 80 μT, 90 μT, 100 μT, 200 μT, 300 μT, 400 μT, 500 μT, 600 μT, 700 μT, 800 μT, 900 μT, 1000 μT, or greater. A constant amplitude or amplitude range; a constant value or range greater than approximately 1000 μT, 900 μT, 800 μT, 700 μT, 600 μT, 500 μT, 400 μT, 300 μT, 200 μT, 100 μT, 90 μT, 80 μT, 70 μT, 60 μT, 50 μT, 40 μT, 30 μT, 20 μT, 10 μT, 9 μT, 8 μT, 7 μT, 6 μT, 5 μT, 4 μT, 3 μT, 2 μT, 1 μT or smaller; or within the range defined by any two of the aforementioned values. The amplitude of the radio frequency waveform in polarization chamber 402 can be maintained within the following constant values ​​or ranges: at least about 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds or longer; at most about 60 seconds, 50 seconds, 40 seconds, 30 seconds, 20 seconds, 10 seconds, 9 seconds, 8 seconds, 7 seconds, 6 seconds, 5 seconds, 4 seconds, 3 seconds, 2 seconds, 1 second or shorter; or within the range defined by any two of the foregoing values.

[0199] Polarizer 510 may include a purification system similar to the purification system of polarizer 500. In some embodiments, the purification system may include a separation system similar to separation system 506 of polarizer 500. The separation system may be or include a precipitation chamber 516. After polarization, a solution containing a polarization precursor (in PHIP-SAH or PHIP applications) or a polarization target compound (in SABRE applications) may be delivered to separation system 516. Separation system 516 may be configured to receive a solution containing a polarization precursor (in PHIP or PHIP-SAH applications) or a polarization target compound (in SABRE applications). In some embodiments, separation system 506 may include connections (e.g., a fluid manifold or other suitable connections) for automatically or manually transferring fluid from polarizer 500. In some embodiments, the purification system may be configured to receive a cut solution, similar to the purification system of polarizer 500. In some embodiments, a redissolution chamber is a chamber in separation system 516, similar to separation system 506 of polarizer 500. In various embodiments, a separation system 506, similar to polarizer 500, can perform liquid-liquid extraction between an organic phase and an aqueous phase via separation system 516. In some embodiments, a fluorinated phase may be used in addition to / as a substitute for the organic phase, and may be combined with the aqueous phase to improve separation. In some other embodiments, the purification step may include catalyst removal. In some embodiments, hyperpolarized molecules may be cleaved within separation system 516 to produce target compounds. In some embodiments, the pH level and temperature of the sample may be monitored and controlled within separation system 516 to meet conditions for injection into a patient. Alternatively, a quality control system (similar to quality control system 613) may be used to monitor the characteristics of the sample. The sample may be injected into an animal or human patient for hyperpolarized MRI scanning in an MRI scanner (e.g., as in MRI system 612).

[0200] The disclosed embodiments are not limited to those including magnetic shield 513. In some embodiments (e.g., embodiments in which appropriate polarization transfer can occur in an ambient magnetic field), polarizer 510 may omit magnetic shield 513.

[0201] Figure 5C A polarizer 520 is depicted, consistent with the disclosed embodiments. The polarizer 520 may include a magnetic shield 561. The magnetic shield 561 may be constructed of μ metal or another suitable shielding material. Similar to magnetic shield 503, magnetic shield 561 can set a specific value or trajectory for the magnetic field within it. The polarizer 520 may include a polarization chamber 541. Figure 5CAs depicted, the polarization chamber can penetrate the magnetic shield 561, thereby allowing an NMR tube 551 (or a larger volume container) containing sample 553 to be placed within the magnetic shield 561. In embodiments using the polarization device 530, polarization can occur in a region of the polarization chamber located within the shield, solenoid, and saddle coil (e.g., the region containing the sample in the NMR tube or larger volume container). In PHIP or PHIP-SAH embodiments, sample 553 can be a solution containing a precursor (before secondary hydrogenation) or a secondary hydrogenation precursor. In SABRE embodiments, sample 553 can be a solution containing a target compound (and optionally a hydrogenation catalyst). Solenoid 543 can be wound around polarization chamber 541. Solenoid 543 can penetrate the magnetic shield 561. Solenoid 543 can be conductive (e.g., copper) and can be excited to provide a magnetic field along the z-axis of polarizer 530. Saddle coil 571 can be disposed within the magnetic shield 561 and around solenoid 541. The saddle coil 571 may be conductive (e.g., copper) and may be excited to provide a magnetic field (e.g., in the xy plane) transverse to the field generated by the solenoid 543. Consistent with the disclosed embodiments, the solenoid 543 may be electrically connected to a radio frequency waveform generator (not shown). Driven by the radio frequency waveform generator, the solenoid 543 may be a magnetic field generator similar to magnetic field generator 507 or magnetic field generator 517. Consistent with the disclosed embodiments, the saddle coil 571 may be electrically connected to a radio frequency waveform generator (or another radio frequency generator). Driven by the radio frequency waveform generator, the saddle coil 571 may be a radio frequency field generator similar to RF coil 514.

[0202] In some embodiments, polarizer 520 may be used in conjunction with a purification system configured to separate purified fractions from a polarized solution. In some embodiments, the purification system may comprise a separation system similar to separation system 506 or 516.

[0203] Figure 6A An exemplary schematic diagram of a system for generating hyperpolarized target compounds, consistent with the disclosed embodiments, is depicted. The system may include a polarizer 600, a precipitation chamber 606, a transport device 610, a redissolution system 611, an MRI system 612, and a quality control system 613. In some embodiments, at least one of the transport device 610 and the quality control system 613 may be omitted.

[0204] Polarizer 600 can be, or is similar to, one of polarizers 500, 510, and 520. Polarizer 600 can be used with a purification system comprising a precipitation chamber 606 and a magnetic field generator 608. Figure 4The sedimentation chamber 403 under discussion. Magnetic field generator 608 (which may be a permanent magnet or an electromagnet) can apply a magnetic field to at least a portion of the sediment in sedimentation chamber 606 that is greater than about 1 mT, 10 mT, 100 mT, 1000 mT or greater; or less than about 1000 mT, 100 mT, 10 mT, 1 mT or less.

[0205] In some embodiments, after precipitation, the precipitate can be transported to different locations in a transport device 610, which may include a magnetic field generator and a cooling system as described herein. The magnetic field generator includes a permanent magnet or electromagnet configured to apply about 1 mT, 10 mT, 100 mT, 1000 mT or greater; or less than about 1000 mT, 100 mT, 10 mT, 1 mT or less to at least some of the precipitated particles in the transport device 610. The hyperpolarized particles can be transported to a redissolution system 611, as detailed herein, where the precipitate can be redissolved in a biocompatible solvent, preferably an aqueous solvent. In some embodiments, the redissolution system may be part of a purification system. For example, after purification, a polarization precursor or polarization target compound may be redissolved (e.g., from the precipitate) before transport in the transport device 610. In various embodiments, the purified polarization precursor may be redissolved and then cleaved to form the polarization target compound. The polarized target compound can then be separated and transported in transport device 610.

[0206] After extraction and purification, the properties of the solution can be monitored in the quality control system 613. In a preferred embodiment, the quality control system monitors the pH and temperature of the solution (e.g., a redissolved solution containing the hyperpolarized target compound produced by the redissolved system 611). In some embodiments, the quality control system 613 may additionally monitor the solution containing trace amounts of the original solvent in which secondary hydrogens are dissolved. Such monitoring can be performed, for example, by a UV / VIS spectrometer. The solution containing the hyperpolarized target compound can be injected into animals or human patients for hyperpolarized MRI scanning in the MRI system 612.

[0207] Exemplary polarization transfer in secondary hydrogenated cinnamon pyruvate

[0208] The systems and methods described in this paper are applied to shifting polarization from secondary hydrogen protons to... 13 C-labeled cinnamon pyruvate precursor. The cinnamon pyruvate precursor is characterized by a carbon-carbon triple bond located at a distance of [missing information - likely a distance in the original text]. 13 The positions of the three bonds of the C target atom. Therefore, when the cinnamon pyruvate precursor is secondary hydrogenated via a triple bond, the secondary hydrogen proton is introduced into the distance... 13 The C target atom has four and five bonds. The following demonstrates the practicality of the system and method proposed in this paper for transferring polarization from secondary hydrogen protons to target nuclei at least four chemical bonds away.

[0209] A method based on RF sweeping was developed to transfer the singlet spin level of hydrogenated secondary hydrogen protons to... 13 Polarization on the C nucleus was investigated and compared with methods based on ultra-low magnetic field sweeping. Both RF sweeping and magnetic field sweeping rely on adiabatic through level anti-crossing (LAC), which causes the initial population imbalance after hydrogenation to lead to... 13 C polarization.

[0210] lead to 13 The physical mechanism of C-polarization is the adiabatic evolution of the system when the magnetic field or RF amplitude is swept sufficiently slowly. The eigenvalues ​​of interest are the lowest eigenvalues, which are overpopulated after hydrogenation (when the sweep parameters, such as the amplitude of the RF pulse or the magnetic field of the sweep, are zero), due to J... 12 It is the largest J-coupling in the system (as mentioned above) Figure 2A and 2B (Described). During sweeping, when the sweeping parameters (e.g., the amplitude of the RF pulse or the magnetic field of the magnetic sweep) become sufficiently large to cross the LAC condition, the low-energy state corresponds to... 13 The state of C-polarization and field alignment. Therefore, at the end of the sweep, the overpopulated state is the target. 13 The polarized state of the C spin leads to the overall 13 C polarization.

[0211] Specifically for RF sweeping, the sweep parameter is Ω, i.e., the amplitude of RF. After hydrogenation, the system's eigenstates are populated based on their overlap with the singlet states of secondary hydrogen protons. Because J 12 The system has the largest J-coupling, and the most populated eigenstates are those with the lowest energy. For sufficiently large Ω, such as values ​​significantly higher than the LAC condition detailed in the "Using Spin-Mediated Polarization Transfer" section, carbon polarization determines the lowest energy eigenstate at the end of the sweep. Therefore, if the RF amplitude sweep is slow enough that the kinetics are adiabatic, the overpopulated eigenstates have the same carbon polarization. In some embodiments, the RF amplitude only needs to sweep slowly near the level anticrossing (LAC) where state population transfer occurs.

[0212] Method

[0213] The low static magnetic field used in the experiment was generated using a double-layered solenoid penetrating a μ-metal magnetic shield along the z-direction (MS-2, Twinleaf, USA). This configuration allows for the generation of fields up to 100 μT. The field homogeneity was measured at 10 nT across the sample volume using a Fluxgate magnetometer (Stefan Mayer Instruments, Germany). The coil was powered by a standard laboratory power supply, and the output was attenuated by a 1 kHz high-power resistor. The RF excitation field was generated using a built-in shimming coil shielded perpendicular to the static magnetic field. The RF signal was generated by a NI card (National Instruments 6363-USB) and amplified using an audio amplifier. The amplitude of the RF field was measured using the same Fluxgate sensor (Stefan Mayer Instruments, Germany).

[0214] A catalyst solution containing 3 mg / ml of Rh(dppb)(COD) catalyst precursor was prepared. This solution was then mixed with a precursor containing the target compound to form the desired PHIP or PHIP-SAH molecule. For the experiment producing cinnamon pyruvate, 25 mM of 1- 13 Solution of C-cinnamylpropynylpyruvate precursor.

[0215] The sample was bubbled for 60 seconds at room temperature under a secondary hydrogen atmosphere of 2.5 bar. Hydrogenation was carried out at high temperature in a laboratory magnetic field (approximately 50 μT) (55 degrees Celsius for solutions using acetone-d6 as solvent and 90 degrees Celsius for solutions using D2O as solvent).

[0216] Then, RF scanning or magnetic field scanning is performed. It is understood that, as described in this paper, other methods of polarization transfer using adiabatic and non-adiabatic RFS are also possible.

[0217] Consistent with the disclosed embodiments, RF scanning as Figures 6B to 6D The process is described. The RF frequency is first increased from zero to approximately 20 Hz to ensure the population of the spin system passes through the associated level anti-crossover (LAC). Then, during the first phase of the RF sweep, the RF frequency is adjusted under a magnetic field of 100 μT. 13 The C-Ramohr frequency remains resonant, while the RF amplitude increases linearly. Unless otherwise specified, the duration of the first phase is 8 seconds. In the second phase of the RF sweep, the RF frequency increases linearly to 70 Hz above the 13C-Ramohr frequency, and the RF amplitude decreases linearly to zero. The duration of the second phase is 2 seconds.

[0218] Consistent with the disclosed embodiments, the magnetic field sweep comprises first, second, and third stages. In the first stage, the sample is either held in a static field of 10 μT or inserted into a polarizer at 10 μT. In the second stage, the magnetic field is adiabatically reduced to 50 nT. In the third stage, the magnetic field is linearly increased to 1 μT. Unless otherwise stated, the duration of the third stage is 8 seconds.

[0219] After RF or magnetic field scanning, the sample was carried to a benchtop NMR spectrometer (Fourier 80, Bruker, USA) where 13C NMR spectra were acquired. To estimate polarization, the proton thermal signal was measured in a high-field spectrometer (Bruker 400 MHz), and the sample concentration was calculated using an external reference. The signal was compared with that of a reference sample (1- 13 Polarization was determined by comparing the thermal signal of methanol (99.4% labeled) with that of a reference high concentration used in this study. 13 Complete relaxation of C-labeled molecules 13 The polarization obtained by acquiring the C spectrum was compared to verify this method of polarization estimation.

[0220] Results

[0221] Figure 7A and 7B Simulation and experimental results depict the polarization transfer of protonated and deuterated cinnamic acid molecules. Figure 7A The polarization transfer to cinnamon pyruvate was depicted, in which proton spin mediates the transfer of carboxylic acid... 13 The C spin is bonded to a secondary hydrogen proton. For this spin system, the performance of RF sweeping and MFC is comparable. With increasing duration of the first stage in RF sweeping, the polarization of the transfer increases and then plateaus, reaching a polarization transfer efficiency of approximately 60% within a 15-second first stage duration. Similar experimental results were achieved with magnetic field sweeping. The simulations of these experiments are in excellent agreement with the experimental results, describing the rise and eventual stabilization of the polarization.

[0222] Figure 7B The polarization transfer to cinnamon pyruvate d1 was depicted, in which the deuteron spin mediates the transfer of carboxylic acid... 13The C spin is linked to a secondary hydrogen proton. The polarization transfer efficiency using RF sweeping is approximately 40% higher than that of protonated molecules. RF sweeping achieves a polarization transfer efficiency that stabilizes at approximately 90%. Simulations of the RF sweeping experiment (omitting relaxation effects) show excellent agreement with the experimental results. Relaxation does not appear to be a problem at the investigated timescales, but may limit the transfer efficiency over longer periods. Magnetic sweeping does not achieve the same degree of polarization as RF sweeping. The achieved polarization decreases with increasing duration of magnetic sweeping. These results suggest that rapid deuterium relaxation will inhibit polarization transfer to the target. 13 The predictions for the C atom are consistent. When using RF sweeping, no polarization transfer to deuterium occurs, and the second scalar relaxation is effectively avoided. These effects combine to achieve significantly higher polarization. The theoretical efficiency of sweeping over deuterated molecules is almost 1.5 times that of protonated molecules because all states are available. This higher theoretical efficiency is experimentally confirmed, with the polarization of deuterated cinnamon pyruvate reaching 8.25%, compared to 6.0% for protonated cinnamon pyruvate, yielding a factor of 1.375. The transfer rate required to ensure adiabatic transfer is similar to that of magnetic sweeping, and the relaxation rate is also similar.

[0223] Figure 7C Polarizations achieved according to the disclosed embodiments for DAMD-d6, DMAD, fumarate, CP 1-13C d1, and CP are shown. For all molecules studied, RF sweeps either produced polarization levels comparable to or exceeding those produced by magnetic field sweeps. Here, hydrogenation was carried out in a water bath heated to 60°C (except for fumarate, which was heated to 90°C). The laboratory field during hydrogenation was approximately 50 μT.

[0224] Exemplary polarization transfer in large volumes:

[0225] A 2 ml acetone-d6 solution containing 100 mM starting material and 5 mM catalyst was heated in an ETFE-coated aluminum reactor vessel. After reaching 55°C, the sample was exposed to a 10 bar secondary hydrogen atmosphere and bubbled with secondary hydrogen for 30 seconds. The solution was then transferred to a vessel located inside the polarization transfer apparatus, where it was diluted with 23 ml of acetone. A static magnetic field of 0.1 mT was used as the guiding field for sample transport and subsequent polarization transfer. The amplitude of the RF field, resonating with the 13C NMR resonance frequency, was then gradually increased from 0 μT to 4 μT over 5 seconds. This gradual increase in amplitude was followed by a 2-second adiabatic 90-degree point-to-point rotation to orient the resulting hyperpolarized magnetization parallel to the static magnetic field. The adiabatic rotation was performed by simultaneously decreasing the amplitude and increasing the RF frequency as described in previous experiments. Subsequently, 0.6 ml of the sample solution was extracted, and the 13C signal was measured using a 60 MHz benchtop spectrometer.

[0226] Figure 8 The polarized 25ml 1- is described according to the disclosed embodiments. 13 C-C cinnamon ester sample. Figure 9 The measurements taken in a 60 MHz SpinSolve spectrometer are depicted. Figure 8 The polarization depicted in the text is rich in 13 Cinnamyl pyruvate 13 C NMR spectrum.

[0227] The foregoing description is presented for illustrative purposes. It is not exhaustive and is not limited to the precise forms or embodiments disclosed. Modifications and adaptations to the embodiments will be apparent from consideration of the specification and the disclosed embodiments. For example, the described embodiments include hardware, but systems and methods consistent with this disclosure can be implemented in both hardware and software. Furthermore, while some components have been described as being coupled to each other, such components may be integrated with each other or distributed in any suitable manner.

[0228] Embodiments herein include systems, methods, and tangible non-transitory computer-readable media. The methods may be performed at least in part (e.g., by at least one processor) receiving instructions from a tangible non-transitory computer-readable storage medium. Similarly, systems consistent with this disclosure may include at least one processor and memory, and the memory may be a tangible non-transitory computer-readable storage medium. As used herein, a tangible non-transitory computer-readable storage medium refers to any type of physical memory on which information or data readable by at least one processor can be stored. Examples include random access memory (RAM), read-only memory (ROM), volatile memory, non-volatile memory, hard disk drive, CD-ROM, DVD, flash drive, disk, register, cache, and any other known physical storage medium. The singular terms, such as “memory” and “computer-readable storage medium,” may additionally refer to multiple structures, such as multiple memories or computer-readable storage media. As referred to herein, unless otherwise specified, “memory” may include any type of computer-readable storage medium. A computer-readable storage medium may store instructions for execution by at least one processor, including instructions for causing the processor to perform steps or stages consistent with embodiments herein. Additionally, one or more computer-readable storage media can be used to implement computer-implemented methods. The term "non-transitory computer-readable storage medium" should be understood to include tangible articles and exclude carrier waves and transient signals.

[0229] Furthermore, while illustrative embodiments have been described herein, the scope encompasses any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., combinations of aspects of various embodiments), adaptations, or alterations based on this disclosure. Elements in the claims are to be interpreted broadly based on the language used in the claims and are not limited to the instances described in this specification or during implementation of the application, which are to be understood as non-exclusive. Further, the steps of the disclosed method may be modified in any way, including reordering steps or inserting or deleting steps.

[0230] The features and advantages of this disclosure are apparent from the detailed description, and therefore the appended claims are intended to cover all systems and methods falling within the true spirit and scope of this disclosure. As used herein, the indefinite article “a / an” means “one or more”. Similarly, unless the use of a plural term is explicit in the given context, it does not necessarily mean plural. Furthermore, since various modifications and alterations will be readily made by studying this disclosure, it is not intended to limit this disclosure to the exact constructions and operations shown and described, and therefore all suitable modifications and equivalents are applicable to and fall within the scope of this disclosure.

[0231] The embodiments may be further described using the following terms:

[0232] 1. A system for generating hyperpolarized molecules, the system comprising: a hydrogenation device configured to generate a secondary hydrogenation solution by mixing a solvent, secondary hydrogen gas, and a precursor of the hyperpolarized molecule, the precursor comprising unsaturated chemical bonds; and a polarization device configured to generate a polarized solution containing the hyperpolarized molecule using the secondary hydrogenation solution, the polarization device comprising: (a) a polarization chamber configured to receive the secondary hydrogenation solution, the polarization chamber comprising a polarization region having a volume of at least 10 milliliters (mL); and (b) one or more radio frequency (RF)... (c) an RF coil, the one or more RF coils being disposed around the polarization region of the polarization chamber; and (d) a magnetic field source, the magnetic field source being disposed around the polarization region of the polarization chamber and configured to provide an average magnetic field strength of up to 200 millitalas (mT); an RF waveform generator coupled to the one or more RF coils of the polarization device, the RF waveform generator being configured to apply an RF waveform to the one or more RF coils; and a purification system, the purification system being configured to separate purified fractions from the polarization solution.

[0233] 2. The system according to Clause 1, further comprising a dissolution chamber configured to contain the purified fraction and receive a second solvent for dissolving the purified fraction.

[0234] 3. The system according to Clause 1 or 2, wherein the polarization device includes a magnetic shield disposed around the polarization region of the polarization chamber.

[0235] 4. The system according to any one of Clauses 1 to 3, wherein the magnetic shield is configured to maintain the magnetic field strength in the polarization chamber at less than 200 mT during the application of a polarization waveform to the one or more RF coils.

[0236] 5. The system according to any one of clauses 1 to 4, wherein the hydrogenation apparatus comprises: a bubbler configured to introduce the secondary hydrogen gas into the solvent; a membrane configured to allow the secondary hydrogen gas to diffuse into the solvent; or an atomizer configured to spray droplets of the solvent into a secondary hydrogen chamber configured to receive the secondary hydrogen gas.

[0237] 6. The system according to any one of clauses 1 to 5, wherein the precursor of the target compound comprises a target compound chemically coupled to a side arm containing the unsaturated chemical bond.

[0238] 7. The system according to Clause 6, wherein the precursor of the target compound comprises an ester of the target compound.

[0239] 8. The system according to Clause 6 or 7, wherein the purification system is configured to receive a cleavage solution configured to cleave the side arm from the precursor of the target compound, thereby producing the target compound.

[0240] 9. The system according to any one of Clauses 1 to 8, wherein the purification system includes a separation system, wherein the purified fraction of the polarized solution includes a fraction of the precipitate of the polarized solution, and wherein the separation system is configured to separate the fraction of the precipitate of the hyperpolarized molecule from the polarized solution.

[0241] 10. The system according to Clause 9, wherein the dissolution chamber is configured to contain fractions of the precipitate and receive a second solvent for dissolving the fractions of the precipitate.

[0242] 11. The system according to any one of clauses 1 to 10, wherein the RF waveform generator is configured to apply the RF waveform over a predetermined time period, and wherein the RF waveform includes at least one of the following: a frequency that is substantially constant during the time period, a frequency that varies substantially linearly during the time period, an amplitude that is substantially constant during the time period, or an amplitude that varies substantially linearly during the time period.

[0243] 12. A method for increasing nuclear spin polarization in a target compound, the method comprising: (a) obtaining a target compound or a secondary hydrogenated precursor of the target compound, the target compound comprising at least: (i) a first proton, (ii) a second proton, the second proton being coupled to at least the first proton via a first J coupling constant, the first proton and the second proton having a singlet spin order, (iii) a third proton, the third proton being coupled to at least one of the first proton or the second proton via a second J coupling constant, and (iv) a target atom, the target atom being coupled to at least one of the first proton or the second proton via a second J coupling constant. The three-J coupling constant is coupled at least to the third proton, wherein the first and second protons are separated from the target atom by at least four chemical bonds; (b) the target compound or the secondary hydrogenated precursor is placed within an average magnetic field strength of less than 500 mT; and (c) a magnetic resonance (MR) pulse sequence is applied to the target compound or the secondary hydrogenated precursor, the MR pulse sequence being configured to transfer the population from the first and second protons to the target atom, thereby imparting at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom.

[0244] 13. The method according to Clause 12, wherein the first proton, the second proton, and the third proton form a quantum mechanical three-body system having energy eigenstates with high population and energy eigenstates with low population.

[0245] 14. The method according to Clause 13, wherein a plurality of eigenstates are highly populated.

[0246] 15. The method according to Clause 13 or 14, wherein the MR pulse sequence is configured to shift the population from the energy eigenstate of the high population to the energy eigenstate of the low population, thereby imparting at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom.

[0247] 16. The method according to any one of clauses 13 to 15, wherein prior to (b), the high-population energy eigenstates have a population of at least 50%, 60%, 70%, 80%, or 90%.

[0248] 17. The method according to any one of clauses 12 to 16, further comprising, prior to (a), endowing the singlet spin stage to the first proton and the second proton.

[0249] 18. The method according to Clause 17, wherein endowing the singlet spin stage with the first proton and the second proton comprises a secondary hydrogen-induced polarization (PHIP) reaction between the secondary hydrogen and the precursor, thereby adding the first proton and the second proton across the unsaturated bonds of the precursor to form the secondary hydrogenated precursor.

[0250] 19. The method according to Clause 18, wherein the precursor of said compound comprises a side arm containing said at least one unsaturated bond and at least said third proton, such that after said PHIP reaction, said side arm contains at least the first proton, the second proton and said third proton.

[0251] 20. The method according to Clause 19, further comprising cutting the side arm from the precursor to form the target compound.

[0252] 21. The method according to Clause 20, wherein endowing the singlet spin level to the first proton and the second proton comprises signal amplification via a reversible exchange (SABRE) reaction between the secondary hydrogen and the target compound, thereby transferring polarization from the secondary hydrogen molecule to the nucleus on the target compound.

[0253] 22. The method according to any one of clauses 12 to 21, wherein the first J coupling constant is expressed as J 12 The second J coupling constant is expressed as J 23And the MR pulse sequence includes an amplitude of approximately Or about sJ 12 At least one MR pulse, where a = J 23 / J 12 and

[0254] 23. The method according to any one of clauses 12 to 22, wherein the MR pulse sequence comprises an S2hM pulse sequence or a PulsePol pulse sequence.

[0255] 24. The method according to any one of clauses 12 to 23, wherein the secondary hydrogenation precursor or the target compound further comprises at least a first carbon-12 atom covalently bonded to the first proton and a second carbon-12 atom covalently bonded to the first carbon-12 atom and the second proton.

[0256] 25. The method according to any one of clauses 12 to 24, wherein the target atom is at least three bonds away from the third proton.

[0257] 26. The method according to any one of clauses 12 to 25, wherein the target atom is selected from the group consisting of: carbon-13 atoms, nitrogen-15 atoms, fluorine-19 and phosphorus-31.

[0258] 27. The method according to any one of clauses 12 to 26, wherein the first proton has a first Larmor frequency determined by the average magnetic field strength, the second proton has a second Larmor frequency determined by the average magnetic field strength, and the third proton has a third Larmor frequency determined by the average magnetic field strength.

[0259] 28. The method according to Clause 27, wherein the difference between the first Larmor frequency and the second Larmor frequency, the difference between the first Larmor frequency and the third Larmor frequency, or the difference between the second Larmor frequency and the third Larmor frequency is less than twice the first J-coupled, twice the second J-coupled, or twice the third J-coupled.

[0260] 29. The method according to Clause 27, wherein the difference between the first Larmor frequency and the second Larmor frequency, the difference between the first Larmor frequency and the third Larmor frequency, or the difference between the second Larmor frequency and the third Larmor frequency is less than 20 Hz.

[0261] 30. The method according to any one of clauses 12 to 29, wherein the precursor comprises a pyruvate containing at least one unsaturated bond, a fumarate containing at least one unsaturated bond, or a succinate containing at least one unsaturated bond.

[0262] 31. The method according to any one of clauses 12 to 30, wherein the MR pulse sequence comprises at least one radio frequency (RF) pulse having a predetermined duration, and wherein the at least one RF pulse comprises one or more of the following: a frequency that is substantially constant during the duration, a frequency that varies substantially linearly during the duration, an amplitude that is substantially constant during the duration, and an amplitude that varies substantially linearly during the duration.

[0263] 32. A method for generating a hyperpolarized molecule, the method comprising: (a) obtaining a precursor of the molecule, the precursor comprising the molecule and a side arm coupled to the molecule, the molecule comprising a target atom, and the side arm comprising at least one unsaturated chemical bond separated from the target atom by at least three intermediate chemical bonds; (b) carrying out a secondary hydrogen-induced polarization (PHIP) reaction between a secondary hydrogen and the precursor, thereby adding a first proton and a second proton across the at least one unsaturated bond and forming the molecule; (c) placing the molecule in an average magnetic field with a strength between 0 mT and 500 mT. (d) Applying a magnetic resonance (MR) pulse sequence to the molecule, the MR pulse sequence being configured to transfer population from the first proton and the second proton to the target atom, thereby imparting at least 1%, 2%, 5%, 10%, or 20% non-equilibrium nuclear spin polarization to the target atom; (e) cleaving the side arm from the precursor, thereby producing the hyperpolarized molecule and the cleaved side arm; (f) purifying the hyperpolarized molecule from the cleaved side arm; (g) administering the hyperpolarized molecule to a subject; and (h) performing a hyperpolarized magnetic resonance imaging (MRI) procedure on the subject.

[0264] 33. The method according to Clause 32, wherein the MR pulse sequence comprises an S2hM pulse sequence or a PulsePol pulse sequence.

[0265] 34. The method according to clause 32 or 33, wherein the target atom is selected from the group consisting of: carbon-13 atoms, nitrogen-15 atoms, fluorine-19 and phosphorus-31.

[0266] 35. The method according to any one of clauses 32 to 34, wherein the precursor further comprises at least a first carbon-12 atom covalently bonded to the first proton and a second carbon-12 atom covalently bonded to the first carbon-12 atom and the second proton.

[0267] 36. The method according to any one of clauses 32 to 35, wherein the target atom is covalently bonded to a third proton.

[0268] 37. The method according to any one of clauses 32 to 36, wherein the first proton has a first Larmor frequency determined by the average magnetic field strength, the second proton has a second Larmor frequency determined by the average magnetic field strength, and the third proton has a third Larmor frequency determined by the average magnetic field strength.

[0269] 38. The method according to Clause 37, wherein the difference between the first Larmor frequency and the second Larmor frequency, the difference between the first Larmor frequency and the third Larmor frequency, or the difference between the second Larmor frequency and the third Larmor frequency is less than twice the first J-coupled, twice the second J-coupled, or twice the third J-coupled.

[0270] 39. The method according to Clause 37, wherein the difference between the first Larmor frequency and the second Larmor frequency, the difference between the first Larmor frequency and the third Larmor frequency, or the difference between the second Larmor frequency and the third Larmor frequency is less than 20 Hz.

[0271] 40. The method according to any one of clauses 32 to 39, wherein the precursor comprises a pyruvate containing at least one unsaturated bond, a fumarate containing at least one unsaturated bond, or a succinate containing at least one unsaturated bond.

[0272] 41. The method according to any one of clauses 32 to 40, wherein the MR pulse sequence comprises at least one radio frequency (RF) waveform having a predetermined duration of at least 300 milliseconds, and wherein the at least one RF waveform comprises one or more of the following: a frequency that is substantially constant during the duration, a frequency that is substantially monotonically changing during the duration, an amplitude that is substantially constant during the duration, and an amplitude that is substantially monotonically changing during the duration.

[0273] As used herein, unless otherwise specified, the term "or" covers all possible combinations unless impractical. For example, if a component is described as potentially containing A or B, then unless otherwise specified or impractical, the component may contain A or B, or A and B. As a second example, if a component is described as potentially containing A, B, or C, then unless otherwise specified or impractical, the component may contain A, or B, or C, or A and B, or A and C, or B and C, or A and B and C.

Claims

1. A system for generating hyperpolarized molecules, the system comprising: A hydrogenation apparatus configured to produce a secondary hydrogenation solution by mixing a solvent, secondary hydrogen gas, and a precursor of the hyperpolarized molecule, the precursor comprising unsaturated chemical bonds; A polarization device configured to use the secondary hydrogenation solution to generate a polarized solution containing the hyperpolarized molecules, the polarization device comprising: (a) A polarization chamber configured to receive the secondary hydrogenated solution, the polarization chamber comprising a polarization zone with a volume of at least 10 milliliters (mL); (b) One or more radio frequency (RF) coils, said one or more RF coils being disposed around said polarization region of said polarization chamber; and (c) A magnetic field source disposed around the polarization region of the polarization chamber and configured to provide an average magnetic field strength of up to 200 millitalas (mT); An RF waveform generator coupled to the one or more RF coils of the polarization device, the RF waveform generator being configured to apply an RF waveform to the one or more RF coils for a predetermined time period, and wherein the RF waveform includes at least one of the following: A frequency that is substantially constant during the said time period The frequency that changes substantially linearly during the said time period The amplitude is substantially constant during the said time period, or The magnitude of the substantially linear change within the stated time period; and A purification system configured to separate purified fractions from the polarized solution.

2. The system of claim 1, further comprising a dissolution chamber configured to contain the purified fraction and receive a second solvent for dissolving the purified fraction.

3. The system of claim 1, wherein the polarization device includes a magnetic shield disposed around the polarization region of the polarization chamber.

4. The system of claim 3, wherein the magnetic shield is configured to maintain the magnetic field strength in the polarization chamber at less than 200 mT during the application of a polarization waveform to the one or more RF coils.

5. The system of claim 1, wherein the hydrogenation device comprises: A bubbler configured to introduce the secondary hydrogen gas into the solvent; A membrane configured to allow the secondary hydrogen gas to diffuse into the solvent; or an aerosol generator configured to spray droplets of the solvent into a secondary hydrogen chamber configured to receive the secondary hydrogen gas.

6. The system of claim 1, wherein the precursor of the target compound comprises a target compound chemically coupled to a side arm containing the unsaturated chemical bond.

7. The system of claim 6, wherein the precursor of the target compound comprises an ester of the target compound.

8. The system of claim 6, wherein the purification system is configured to receive a cleavage solution configured to cleave the side arm from the precursor of the target compound, thereby producing the target compound.

9. The system of claim 1, wherein the purification system comprises a separation system, wherein the purified fraction of the polarized solution comprises a precipitated fraction of the polarized solution, and wherein the separation system is configured to separate the precipitated fraction of the hyperpolarized molecules from the polarized solution.

10. The system of claim 9, further comprising a dissolution chamber configured to contain the precipitated fraction and receive a second solvent for dissolving the precipitated fraction.